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Vinculin is an essential cytoskeletal protein that acts as a scaffold to link transmembrane 
receptors to actin filaments, thereby playing a crucial role in cell adhesion, motility, and force 
transmission between cells. While vinculin is ubiquitously expressed, metavinculin, a larger 
isoform of vinculin, is selectively expressed in smooth and cardiac muscle cells. Metavinculin 
contains an additional exon that encodes a 68-residue insert. Point mutations in the 68-residue 
insert have been associated with altered actin organization and heart disease, notably dilated 
cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM). As metavinculin expression 
is higher in muscle cells that require greater force transmission, we postulate that metavinculin 
plays an important role in force generation and transmission through its interaction with the actin 
cytoskeleton. Results from cryo- and negative-stain electron microscopy (EM), in conjunction 
with actin co-sedimentation experiments, indicate that the tail domain of vinculin (Vt) and 
metavinculin (MVt) possess similar F-actin binding interactions yet are distinct in their ability to 
remodel actin filaments. Whereas actin binding of Vt promotes actin filament bundling in vitro, 
the MVt domain does not. Intriguingly, addition of MVt to Vt interferes with Vt-induced actin 
filament bundling. In contrast, cardiomyopathy-associated MVt mutants do not antagonize Vt-
induced actin bundling. Based on these findings, we hypothesize that metavinculin plays a role in 
negatively regulating vinculin-mediated actin bundling in contractile tissues. Hence, we next 
examined the roles of vinculin and metavinculin within cells. To investigate functional  
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differences between metavinculin and vinculin in cells, we additionally stably expressed either 
vinculin or metavinculin in vinculin-null mouse embryonic fibroblasts. While both metavinculin 
and vinculin were observed at focal adhesions (FA), metavinculin-expressing cells had larger but 
fewer FAs per cell compared to vinculin-expressing cells. Metavinculin-expressing cells 
migrated faster and exhibited greater persistence compared to vinculin-expressing cells, even 
though vinculin-containing FAs assembled and disassembled faster. Magnetic tweezer 
measurements on vinculin-expressing cells show a typical cell stiffening phenotype in response 
to externally applied force; however, this was absent in vinculin-null and metavinculin-
expressing cells. Our findings that metavinculin expression leads to larger but fewer number of 
FAs per cell, in conjunction with the inability of metavinculin to bundle F-actin in vitro and 
rescue cell stiffening response, are consistent with our previous findings of actin bundling 
deficient vinculin variants, suggesting that deficient actin-bundling may account for some of the 
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CHAPTER 1 - INTRODUCTION 
Focal adhesion architecture and signaling 
When many cells migrate in culture dishes, structures called focal adhesions (FAs) 
assemble and disassemble, allowing cells to regulate points of adhesion and force. Cell adhesion 
and mechanotransduction regulation contributes to normal physiological control of cell motility, 
morphology, and survival. FAs are macromolecular structures that consist of ~150 different 
proteins that form adhesion plaques between cell membrane and the extra cellular matrix (ECM). 
FAs physically link actin cytoskeleton inside the cell to the outside environment, and they can be 
largely divided into three layers: integrin signalling layer, force transduction layer, and actin 
regulatory layer (1) (Fig. 1). 
Historically, FAs were initially observed by Abercrombie et al. in 1971, who used 
electron microscopy (EM) to examine lamelliopodia in cultured migrating fibroblasts 
lamelliopodia in cultured migrating fibroblasts (2). Though not yet termed FAs, the discovery of 
these adhesion plaques ultimately grew into a field that significantly impacted our understanding 
of mechanotransduction and signaling. Following the study by Abercrombie et al., Izzard and 
Lochner utilized interference reflection microscopy (IRM) and detected FAs, though the intent of 
the study was to determine the distance between the underside of chick heart fibroblasts and the 
glass coverslip where they are attached. The vocabulary for FAs varied as this term hadn’t been 
coined yet (3). Combining both EM and IRM, Heath and Dunn showed that the plaques observed 






Figure 1. Nanoscale architecture of focal adhesions.  
Originally published by Kanchanawong, P. et al. Nature. 2010 Nov 25;468(7323):580-4. 
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“focal adhesions” (4). Couchman and Rees subsequently used this term upon studying cardiac 
fibroblasts migrating out of heart explants (5). Interestingly, these authors observed that during 
the initial phase of rapid cells migration, the fibroblasts barely showed any FAs but as these cells 
slowed down, FAs developed. It is important to note that FAs are not necessary for cell 
migration as many cells have been shown to migrate without them. While integrin-mediated 
adhesion to the ECM still forms in cells that do not develop FAs, these adhesions do not form 
stable clusters of integrins. Nobes and Hall introduced the term “focal complex” to refer to 
smaller, more transient adhesions than FAs (6). In general, the term nascent adhesions has been 
widely adopted in the field to describe the initial small adhesions, which eventually develop into 
focal complexes and ultimately into FAs as the adhesion matures and stabilizes. Burridge 
provides an excellent review on a historical perspective of the focal adhesion field (7). 
With the development of immunofluorescence microscopy in the mid-1970s and the 
discovery of vinculin by Geiger in 1979 (8), there was a breakthrough in the field of focal 
adhesion and cytoskeleton research. A number of FA components have been discovered since 
that time. Notably, several key components have been identified at FA, including integrin, talin, 
vinculin, and α-actinin, which will be discussed in more detail below. These FA components 
reside distinctly throughout the three layers that comprise the FA structure.  
With the exception of integrin transmembrane receptors and syndecan-4, the vast 
majority of proteins that comprise FAs consist of cytoplasmic proteins. The integrin signalling 
layer is apposed to the cell membrane and contains integrin cytoplasmic tails, focal adhesion 
kinase (FAK), and paxillin (1). As mentioned above, integrins play a key role in FAs as a 
transmembrane receptor that connects the extracellular matrix (ECM) via their extracellular 
domain to the cell’s cytoskeleton via their cytoplasmic tails. They are the main receptor proteins 
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that cells use to both bind and respond to the ECM ligands, including collagen, fibronectin, and 
laminin. An integrin molecule consists of two non-covalently associated transmembrane subunits 
called α and β determines its affinity for specific ECM ligands. Integrins exist in 3 states: closed 
(inactive), bent, and open (active) conformations (9). Activation of integrins occur through either 
“outside-in” or “inside-out” signaling, where both the environmental cues and the intracellular 
signals regulate how FAs function (10, 11). Outside-in signaling initiates as the integrin 
extracellular domain binds to ECM ligand, driving a conformational change that exposes their 
cytoplasmic tails, which recruits specific proteins that form and mature FAs. In the context of 
FAs, integrins have been found to bind to other FA components such as talin (12) and α-actinin 
(13), providing a physical link between plasma membrane and FA. Force has been speculated to 
play a role in integrin activation as well, although it is still being determined. Some studies 
suggest that external mechanical loading is necessary for integrin activation (14). Inside-out 
signaling is also hypothesized to occur through actomyosin-driven force generation and 
regulated at the integrin signaling layer since by altering the activation state of integrins, 
intracellular signals can modulate the bindng affinity between integrins and ECM ligands (15). 
Furthermore, integrin signaling layer may be important for regulating feedback between inside-
out and outside-in signaling as well. In this layer, integrin activation has been shown to 
autophosphorylate FAK, which has been linked to mechanosensing, cell shape control, and focal 
adhesion dynamics (16-18). Then FAK, in turn, can regulate intracellular signals involving 
GTPase RhoA, which plays important roles in functions such as actomyosin contractility and FA 
formation (19, 20). FAK has additionally been implicated in the regulation of cell adhesion and 
migration. Notably, FAK-deficient cells spread more slowly on ECM proteins, exhibit an 
increased number of FAs, and migrate poorly in response to chemotactic and haptotactic signals 
5 
 
(21-24). C-terminal domain of FAK is also a site of many protein-protein interactions, and 
overexpression of focal adhesion kinase-related nonkinase (FRNK), an autonamously expressed 
C-terminus of FAK, has been shown to inhibit the rate of cell spreading and migration rates in 
response to chemotactic and haptotactic cues (24-26). Therefore, the integrin signaling layer of 
FA is important for both responding to external forces and the generation of intracellular forces.  
With respect to the cell membrane surface, the force transduction layer lies on top of the 
integrin signaling layer, and it consists various scaffolding and signaling proteins. Of note, talin 
and vinculin (though vinculin has been found in all FA layers) have been shown to play 
important roles in mechanotransduction (1, 27). Talin can bind both integrins and filamentous 
actin (F-actin) and reinforce this connection to F-actin by further recruiting vinculin (12, 28, 29). 
Application of force on talin has been shown to expose the cryptic vinculin-binding sites (VBS) 
by unfurling talin, which then recruits vinculin to talin (30). This force is thought to occur as 
myosin-generated forces are transmitted across FAs or from forces resulting from actin 
retrograde flow that are transmitted across FAs to create traction to drive the cell forward (actin 
retrograde flow will be discussed below). Under applied load, the affinities for vinculin on VBS 
of talin increase after a certain threshold, supporting the idea of “molecular clutch” at these sites 
of mechanotransduction (30). Vinculin also similarly increases its affinity to specific ligands past 
a certain threshold of applied load/force (31, 32), additionally supporting the idea of “molecular 
clutch” at FAs. Molecular clutch model demonstrates that force transmission is regulated by a 
dynamic clutch mechanism, where force transduction only occurs once talin (or vinculin) unfurls 
above a stiffness threshold (27, 33-35). Below this threshold, integrins unbind and release force 
before talins can unfold. Above this threshold, talin unfolds and binds to vinculin, which then 
further drives the FA maturation through vinculin’s function as a scaffolding protein. Whether 
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talin and/or vinculin can overcome this stiffness threshold depends on the stiffness of the cell’s 
environment, as the cell’s ability to sense mechanical cues and transduce force into biochemical 
signals depends on the rigidity of the environment that the cell is in. Coupled with the molecular 
clutch model is the role of actin retrograde flow in cells. Actin retrograde flow refers to actin that 
flows back toward the body of the cell as the cell migrates, resulting from the actin 
polymerization against the cell membrane at the leading edge (36). It has been proposed that FAs 
at the cell’s leading edge act as “clutches” for the flowing actin that impede actin’s retrograde 
movement. By clutching onto the retrograde flow of actin, FAs can transduce the force from this 
actin flow to the ECM, creating the traction needed to push the cell forward (36). Hence, the 
speed of actin retrograde flow should be inversely related to the traction force at FAs: the more 
FAs clutch onto the flowing actin to create more traction against ECM, the slower the actin 
retrograde flow should be. Talin and vinculin act as molecular clutches that bind to F-actin at the 
force transduction layer of FAs, playing important roles for how FAs transmit force into 
intracellular biochemical signals and vice versa. 
Finally, the actin regulatory layer is the uppermost FA layer (with respect to the cell 
membrane surface) containing zyxin, vasodilator-stimulated phosphoprotein (VASP), and α-
actinin (1). Actin regulatory layer engages in actin assembly, actin disassembly, and stress fiber 
reinforcement. Increased stress fiber formation is one of the ways that cells respond to tension or 
mechanical stress, and the proteins VASP and zyxin play critical roles for this function (37). 
When stress fibers experience strain, VASP and zyxin relocate from the actin regulatory layer of 
FAs to sites of tension along stress fibers, which results in stress fiber reinforcement (37, 38). 
With the help of VASP protein, zyxin enhances actin polymerization at these sites (37, 38). 
Furthermore, α-actinin has also been found to localize along stress fibers with a periodic pattern 
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and was found to be concentrated at FAs in non-muscle cells (39). α-actinin is a protein that can 
bundle actin in an anti-parallel manner and lines the stress fibers as it bundles the actin filaments 
there. Aside from binding to actin, α-actinin can also associate with a number of cytoskeletal and 
signaling molecules, including the cytoplasmic tail of integrin (13), which renders it an important 
structural and regulatory protein in cytoskeletal organization (40). Through the proteins that 
comprise the actin regulatory layer at FAs, this layer plays a significant role in transmitting 
signals to actin cytoskeleton from force transduction and integrin signaling layers. On the other 
hand, the actin regulatory layer can also participate in inside-out signaling by transmitting 
intracellular cues to force transduction and integrin signaling layers. 
 All three layers of FAs work together to link extracellular ECM to the intracellular actin 
cytoskeleton, where each layer plays a distinct role in sensing and responding to environmental 
cues or intracellular signals. Various force-sensitive mechanisms are at play in FAs and 
therefore, further studies of how FA phenotypes relate to force will clarify the underlying 




The cell adhesion protein vinculin 
Vinculin is an essential, ubiquitously expressed cytoskeletal protein that acts as a scaffold 
to link actin cytoskeleton to transmembrane receptors at FAs (vinculin binds to F-actin and talin, 
which binds to integrin transmembrane receptor) and at adherens junctions (AJs) (vinculin binds 
to F-actin and α-catenin, which binds to cadherin transmembrane receptor). Vinculin was 
initially discovered in chicken gizzards in 1979 (42), and since then much about this protein has 
been studied at both the structural and cellular level. At the sites of adhesion, vinculin’s role as a 
physical link between actin and transmembrane receptor plays a crucial part in cell adhesion, 
motility, and force transmission. Without vinculin, mouse embryos do not survive past E10, and 
they exhibit defects in cardiac and neural tube development (43). Furthermore, lack of vinculin 
in mouse embryonic fibroblasts (MEFs) leads to rounded morphology, increased motility, and 
resistance to apoptosis and anoikis (43-45). Vinculin regulates these processes by binding to 
multiple biomolecules at specific times and at specific domains, thereby playing a key role in 
signaling at adhesion sites and creating physical linkages between proteins.  
Vinculin is a 117 kDa protein that functions as a molecular scaffold. It is comprised of a 
large ~90 kDa head domain (Vh), flexible proline-rich linker, and the tail domain (Vt) (46) (Fig. 
2). Vh interacts with talin at FAs, α-catenin at AJs, and α-actinin at both cellular locations (47-
49) (Fig. 2). The proline-rich linker that connects Vh to Vt can bind to VASP, vinexin, 
CAP/ponsin, and Arp2/3 complex (50-53). Vt directly binds to filamentous actin (F-actin) (54), 
phosphatidylinositol (4,5) biphosphate (PIP2) (55), and raver 1 (56-58) (Fig. 2). In my 
dissertation, direct interaction between Vt and F-actin will be discussed in detail. However, other 
ligands that bind to Vt additionally appear to play important roles for cellular processes. First, 
PIP2 is an important signaling lipid for numerous cellular processes, including membrane ruffle 
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formation (59), exocytosis (60), and phagocytosis (61). In the case of FAs, PIP2 is generated by 
phosphatidylinositol phosphate kinase type 1 gamma (PIPKIγ) (62), which is recruited to focal 
adhesions by talin (63, 64). Talin recruits vinculin, meaning that vinculin colocalizes with and 
PIP2, which regulates the interaction of vinculin with talin (28, 47). PIPKIγ regulates FA 
dynamics (65, 66), is required for FA formation (67), and is thought to be involved in 
recruitment and activation of vinculin at FAs (66, 68). While much is known about the general 
role of PIP2 at FAs, the consequences of the vinculin:PIP2 interaction are much less understood. 
Raver 1, an 80 kDa multidomain protein that is widely expressed in different cell lines, is shown 
to form complexes in vitro with not only vinculin but also with α-actinin and metavinculin (57), 
a vinculin isoform that will be introduced in the next section. Raver1’s interaction with vinculin 
tail domain at FAs is particularly intriguing as raver1 is a RNA-binding protein that plays an 
important role in mRNA processing regulation through its interaction with the splicing regulator 
polypyrimidine tract binding protein (PTB) (56, 69-71). Crystal structure of vinculin:raver1 
show that raver 1 binds to a RNA sequence found in vinculin mRNA, and that this interaction is 
permissive for vinculin’s interaction with F-actin at the tail domain (56). These findings suggest 
that vinculin acts as a scaffold for the recruitment of raver1 and that vinculin mRNA cargo to 
FAs, which would promote localized synthesis of adhesion complexes (56). Autoinhibitory 
interactions between Vh and Vt promote the closed inactive state which obscures ligand binding 
(46) (Fig. 2). Although mechanisms of activation are not fully understood, it is currently believed 
that the engagement of talin or catenin to Vh in conjunction with binding of additional ligands 
(47, 72, 73), post-translational modifications (74), and/or force (75-78) promotes activation and 






Figure 2. Vinculin is an autoinhibitory scaffolding protein. 
 
Vinculin is a scaffolding protein that typically exists in an autoinhibited, closed (inactive) 
conformation where the head and the tail domain are in tight interaction. Upon activation, this 
interaction is released, exposing various ligand binding sites on the head and the tail domain, as 




Metavinculin is a splice isoform of vinculin expressed in muscle cells 
While vinculin is ubuitously expressed in all cell types, vinculin has one alternative splice 
isoform, termed metavinculin, that is co-expressed with vinculin in diverse muscle tissues and at 
low levels in platelets (42, 79-81). The metavinculin transcript contains an extra exon (exon 19) 
compared to the vinculin transcript, and this exon translates into an additional 68-residue insert 
in the tail domain (82). Metavinculin is expressed at sub-stoichiometric levels relative to vinculin 
(9-42%), and its expression correlates with the elevated contractile needs of these muscle cells 
(83, 84). It is currently believed that metavinculin plays a special role in mechanotransduction, as 
its expression levels positively correlate with the force exerted on cells (84). Metavinculin was 
initially discovered in chicken gizzards (42). Since then, it has been shown that the expression 
level of metavinculin in various tissues and cultured cells differ (83-88). Studies by Glukhova et 
al. showed that in adult human tissues, metavinculin was found in cardiac and smooth muscle of 
aorta and uterus, respectively (85); subsequent studies by Belkin et al. showed that metavinculin 
expression level in these tissues positiviely correlated with muscle contractility (83-85). Since 
this initial characterization of metavinculin, many groups investigated the (1) association of 
metavinculin with human cardiomyopathy patients at the tissue level, (2) the effect of disrupting 
the vinculin gene at the organismal level (mostly using mice), and (3) the characterization of the 
molecular structure and function of metavinculin.  
In 1997, Maeda et al. found an association between deficiency of metavinculin 
expression and human dilated cardiomyopathy (DCM) patients (89). This observation led to 
several studies looking at the relationship between human cardiomyopathy patients and 
metavinulin in these patients’ tissues (90, 91). Olson et al. found that in human DCM patients, 




68 amino acid insert (A934V, ∆L954, and R975W). Of the three variants, R975W-associated 
patient showed the most pronounced defect in the organization of intercalated discs (90). 
Following this study, Vasile et al. also found that R975W is additionally associated with both 
hypertrophic cardiomyopathy (HCM) and DCM in human patients and that the reduced level of 
both vinculin and metavinculin at the intercalated disc is associated with HCM (91, 92).  
Metavinculin and its association with cardiomyopathies was also studied at the 
organismal level using mice by Zemljic-Harpf et al (93, 94). Zemljic-Harpf et al. observed that 
mice that have heterozygous inactivation of the vinculin gene are predisposed to stress-induced 
cardiomyopathy (94). These mice not only showed reduced expression levels of both vinculin 
(58% reduction) and metavinculin (63% reduction), but also abnormal myocardial ultrastructure 
and increased mortality rate (94). Furthermore, they found that the cardiac-myocyte-specific 
excision of the vinculin gene in mice led to disruptions in cellular junctions, leading to sudden 
death of DCM in these mice (93). One limitation of these studies, however, was that disruption 
of vinculin genes led to the deletion of both vinculin and metavinculin variants. Therefore, these 
studies were not able to tease apart individual functions due to vinculin or metavinculin.  
Finally, metavinculin’s structure and function has been characterized at the molecular 
level, in relation to how these molecular structures may affect the associated cardiomyopathies. 
The crystal structure of metavinculin was first solved by Rangarajan et al. in 2010, and this 
structure revealed a helix-replacement of the helix 1 (H1) sequence of Vt by helix 1’ (H1’) 
sequence of MVt (95). The specific details of the structural difference between vinculin and 
metavinculin will be discussed in the next section. One interesting observation made by this 
study was that all DCM and HCM associated mutations in metavinculin (A934V, ∆L954, and 
R975W) lie within or near the H1’ region, implying that H1’ plays an important role for 
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metavinculin function (90). Additionally, Olson et al. had found that MVt A934V, ∆L954, and 
R975W have all led to an actin bundling phenotype in vitro, although MVt does not typically 
bundle actin filaments (90). Further structural studies will need to be done to elucidate how the 
structure of MVt contributes to DCM and HCM, as well as to clarify how A934V, ∆L954, and 
R975W mutations disrupt metavinculin function.   
 Both DCM and HCM are diseases of the myocardium that diminish blood flow within the 
heart due to reduced force transmission. Association between metavinculin expression and 
mutations with diseases of the heart muscle further support the view that metavinculin plays a 
crucial role in the mechanotransduction properties of the cell. However, the direct cellular 




Differences between vinculin and metavinculin structure and function 
Metavinculin and vinculin structurally share the same head domains (95, 96); however, 
their tail domains differ (Fig. 3). Vinculin tail domain possesses an N-terminal strap followed by 
a 5-helix bundle and C-terminal hairpin (46), while the metavinculin tail domain contains an 
additional exon that encodes a 68 amino acid insert (79) (Fig. 3). This extra exon codes for the 
residues between helices 1 and 2 in the vinculin tail domain and confers unique functions to the 
metavinculin tail domain (82). Structurally, while metavincuiln tail has a 5-helix bundle fold 
similar to vinculin tail, the sequence that makes up the helix 1 (H1) and strap of vinculin tail is 
displaced in the metavinculin tail by homologous sequences, which we term H1’, contained 
within this insert (95) (Fig. 3). Specifically, these new residues replace the vinculin residues 879-
915, which translate to the N-terminal strap and the H1 in vinculin tail. The original vinculin tail 
sequence 879-915, in the context of metavinculin, is no longer observable in the existing crystal 
structures (95), which indicates that this region is either disorganized or dynamic. The altered tail 
domain structure in metavinculin increases the affinity for raver 1 (54) and decrease the affinity 
for PIP2 (97) compared to vinculin. This difference in raver 1 and PIP2 affinity with either Vt or 
MVt is especially interesting as vinculin and metavinculin differ structurally at the tail domain 
(95). Interestingly, raver 1 binds to not only both vinculin and metavinculin, but also to vinculin 
mRNA (56-58). Additionally, structural studies show that raver 1 can bind to full-length 
metavinculin but not vinculin, suggesting that raver 1 can bind to inactive conformation of 
metavinculin and active conformation of vinculin (56-58). Along with the binding data that show 
that raver 1 forms a ternary structure with MVt and vinculin mRNA (58), I speculate that raver 1 
plays a critical role for the splicing regulation of vinculin mRNA in muscle tissues. As raver 1 
has been shown to regulate tropomysin mRNA splicing that occurs specifically in smooth muscle 
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(69), perhaps raver 1 plays a similar role in regulating exon 19 splicing in the translation of 
vinculin mRNA. Since metavinculin expresses exon 19 in vinculin mRNA, perhaps this exon 
skipping is repressed in muscle cells when metavinculin is translated through the ternary 
structure that form among MVt: raver1:vinculin mRNA. The presence of the insert and the 






Figure 3. Sequence and structural differences between Vcn and MVcn. 
(A) Diagram comparing domain architecture of full-length Vcn and MVcn. (B) Crystal structures 
of Vcn (PDB: 1TR2) and MVcn (95). Regions that lack electron density are represented by a 
dotted line. (C) Diagram comparing sequence differences in the Vcn and MVcn tail domain. 
MVcn tail contains an insert of 68 amino acid between residue 915 and 916 (H1’ in red, residues 
916-983). (D) Structural schematic depicts sequence differences that lead to a helix replacement 
of H1 with H1’ (red) in MVcn tail (Vh: Vcn head domain; Vt: Vcn tail domain; MVt: MVcn tail 




The role of vinculin-mediated actin-binding and actin-bundling 
Similar to Vt, MVt directly binds F-actin (95, 98, 99). However, one interesting 
difference is in their ability to crosslink F-actin. Vt has been shown to bundle F-actin in vitro; 
however, unlike Vt, MVt does not bundle filamentous actin into higher order structures in vitro 
(90, 98-100). We and others have previously shown that binding of F-actin to Vt causes a 
conformational change in Vt that promotes dimerization and actin filament bundling (101, 102).  
However, the structure of the actin-induced Vt dimer is currently unknown. The susceptibility of 
H1 to proteolysis, combined with the lack of electron density observed for H1 in our cryo-EM 
reconstruction of the Vt-actin complex, suggests that H1 partitions away from the helix bundle 
upon engagement with filamentous actin to promote vinculin dimerization (99) (Fig. 4). 
Furthermore, the C-terminal tail of Vt plays a significant role in the formation of this actin-
induced Vt dimer, as the deletion of the last five residues abrogates the ability of Vt to bundle 
actin (101). Expression of vinculin∆C5 mutant in vinculin-null MEFs lead to fewer and larger 
FAs and deficiency in cells to respond to external force (101). Similarly to Vt, H1’ in 
metavinculin is not observable in the cryo-EM reconstruction of the metavinculin-actin complex 
(99), and the MVt binding site on F-actin is similar to that of Vt (99). The presence of H1 
appears to interfere with the ability of metavinculin to bundle F-actin, as its deletion promotes 
actin filament bundling (95).  
While vinculin and metavinculin show similar modes of binding to F-actin, metavinculin 
is unable to bundle actin filaments (90, 98-100). As metavinculin is co-expressed with vinculin 
in muscle tissues (42, 79, 84), it is likely that vinculin and metavinculin coordinately regulate 
actin filament rearrangement. Because of the studies that showed the reduction of metavinculin 









traditionally thought that metavinculin is more likely have a supporting role for vinculin in actin 
bundling. However, more recent studies seem to suggest that metavinculin may have a role in 
negatively regulating the actin bundling properties of vinculin physiologically. We and others 
have previously observed that the presence of metavinculin at sub-stoichiometric ratios impairs 
vinculin mediated F-actin bundling (99, 103), suggesting that MVt may negatively regulate Vt-
mediated actin bundling. Furthermore, studies by Janssen et al. also observed actin filament 
fragments in the presence of MVt alone (98), and they attributed this observation to a potential 
ability of MVt to sever actin filaments. Additionally, studies by Durer et al. not only showed that 
MVt increases the proteolysis of F-actin by itself but also suggested that MVt may “tune” the 
flexibility and the architecture of vinculin-induced actin bundling (103). Durer et al. suggested 
this potential role of MVt as a negative-regulator of Vt-induced actin bundling as they found that 
MVt decreases the density and the thickness of actin filament bundles generated by Vt (103). 
However, unlike the studies by Janssen et al., Durer et al. found negligible actin severing activity 
by MVt (103). Though further studies are necessary to understand the molecular basis for the 
ability of MVt to negatively regulate actin bundling by Vt, several observations associated with 
metavinculin-associated diseases seem to support this perspective. Metavinculin mutants 
associated with DCM and HCM are able to form higher order actin assemblies in vitro (90), 
suggesting that the disturbance of metavinculin’s ability to disrupt vinculin-mediated actin 
bundling leads to cardiomyopathies. Similarly, Zemlijic-Harp et al. found decreased level of 
metavinculin expression in mice that’s developed DCM (93). Further molecular studies of how 
disease-associated MVt mutants lead to higher-order actin bundling will be helpful in 
determining the cause of associated HCM and DCM. 
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In addition to the molecular characterization of actin bundling by metavinculin, there has 
been a significant lack of cellular characterization of metavinculin. Although some studies on 
metavinculin have been done at the tissue and organismal level, there has yet to be a study that’s 
been done at the cellular level. Our lab has previously shown that the expression of actin 
bundling deficient mutant, vinculin ∆C5, in vinculin null MEFs led to changes in cellular 
properties, such as the increase in FA area, decrease in the average number of FA per cell, 
decrease in cell spreading, and the decrease in cell stiffening in response to applied force (101). 
It will be important to assess whether actin bundling differences observed between vinculin and 
metavinculin at the molecular level will lead to differences at the cellular level, and ultimately 
determine what those differences mean physiologically. Such studies complement work done at 





CHAPTER 2 – The Strutural Basis of Actin Organization by Vinculin, Metavinculin, and 
Metavinculin Cardiomyopathy-associated Mutants 
Introduction 
 Vinculin functions as an important scaffolding protein and can engage at least 19 direct 
binding partners at both cell-cell junctions and cell-matrix adhesions. Included in these direct 
binding partners are several actin-binding proteins (104). These interactions alter cytoskeletal 
organization, which in turn play a role in cell morphology, motility, and force transduction. 
However, for the purposes of this study, we focused on direct interactions between Vt and F-
actin. Vinculin also strengthens the physical connection between membrane receptors and actin 
cytoskeleton (105), and this mechanical reinforcement is primarily through vinculin’s 
interactions with talin (47, 105, 106). Talin is a critical adhesion protein that binds to integrin 
(12) within its N-terminus and also to actin through its C-terminus end (1). Like vinculin, talin is 
a scaffolding protein that exists in an autoinhibited state (107). Once tension is applied across 
talin molecule, talin unfurls, revealing 11 binding sites for vinculin (30) and actin (108), though 
the actin-binding affinity is relatively weak (108). It is thought that the recruitment of vinculin by 
talin stabilizes the actin linkage to integrins by keeping talin in an active, unfurled state and also 
additionally increasing the linkage to actin through vinculin’s interactions with actin (109).  
In addition to binding to filamentous actin, vinculin tail crosslinks actin filaments into 
parallel bundles in vitro (101, 102, 110). Both actin binding and bundling properties play an 
important role in vinculin function, as selectively disrupting them in the context of the full-length 
molecule leads to defects in cell spreading, focal adhesion formation and maturation, and 
22 
 
mechanotransduction (32, 101, 111, 112). While the vinculin tail domain in monomeric in 
solution, engagement to F-actin promotes a conformational change in Vt that facilitates Vt 
dimerization and actin bundling, as observed by cross-linking and electron tomography studies 
(101, 102, 110, 113). Unlike Vt, MVt cannot bundle actin filaments but can bind to actin 
failments (76, 82, 92, 100). The ability of vinculin, but not metavinculin, to reorganize actin 
filaments into bundles indicates that metavinculin and vinculin have distinct functions. 
Moreover, metavinculin and vinculin are co-expressed in muscles cells, suggesting a coordinate 
role in muscle cell regulation. Metavinculin contains a 68 amino acid insert in the tail domain, 
and part of this insert not only replaces the Vt H1 with MVt H1’ but also replaces the N-terminus 
of the MVt (Fig. 3). Other than this difference in the helix bundle, the role of MVt insert is 
currently unknown. To better understand the unique functions of vinculin and metavinculin, we 
investigated how these two isoforms directly bind actin using cryo-electron microscopy (cryo-
EM). We were able to obtain sub-nanometer-resolution cryo-EM reconstructions of Vt-actin and 
MVt-actin complex, providing models for both interfaces (99). We then validated the Vt-actin 
model through mutagenesis. Based on the limited proteolysis data by Durer et al. (103) and our 
experimental data, we proposed that F-actin engagement causes the Vt and MVt helical bundles 
to undergo a torqueing conformational change, resulting in explusion of Vt H1 and MVt H1’ 
from the helical bundle. These reconstructions show that while Vt and MVt have similar actin-
binding interfaces, both proteins undergo structural transitions that lead to differences in actin 
bundling. The presence of H1 appears to interfere with the ability of metavinculin to bundle F-
actin, as its deletion promotes actin filament bundling (95). These observations provide us with a 
conceptual model in which Vt and MVt partially unfold upon actin-binding, and either the 
presence or absence of the MVt insert dictates whether dimerization and actin bundling occur.  
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 The cryo-EM reconstruction of Vt-actin and MVt-actin complexes provided us 
with a valuable insight into how Vt or MVt undergoes a conformational change upon binding to 
actin. However, as metavinculin is co-expressed with vinculin in muscle tissues (42, 79, 84), it is 
likely that vinculin and metavinculin coordinately regulate actin filament rearrangement in 
contractile cells. In fact, we found that the presence of MVt can suppress the actin bundling 
properties mediated by Vt in our actin cosedimentation assays, providing us with a hypothesis 
that MVt may negatively regulate the actin bundling properties of Vt. To better understand the 
role of metavinculin in actin filament assembly, we conducted a series of actin co-sedimentation 
and negative stain EM experiments in the absence and presence of vinculin. Consistent with our 
previous findings (99), MVt is unable to induce actin bundling, and the presence of sub-
stoichiometric amounts MVt relative to Vt inhibits the assembly of actin filaments into parallel 
bundles. Furthermore, we investigated whether cardiomyopathy (CM)-associated MVt mutants 
induce actin bundling either in the presence or absence of Vt. In contrast to wild type MVt, MVt 
CM mutants (which are all within the MVt insert) induce moderate actin assemblies but not 
defined parallel actin bundles induced by Vt. To better understand the molecular basis for the 
ability of MVt to negatively regulate Vt-mediated actin bundling, we performed DMD 
simulations. Actin binding to vinculin promotes release of H1 from the tail domain helix bundle, 
exposing an interface in vinculin that promotes dimerization. However, our computational 
analyses indicates that in the case of metavinculin, the insert forms a higher order structure with 
H1’ that is released from the helix bundle upon actin binding, which occludes actin assembly 
into parallel F-actin bundles. Our MD simulations also indicate that cardiomyopathy mutations 
within the metavinulin tail domain, destabilize formation of this higher order structure. 
Consistent with these observations, the presence of MVt CM mutants failed to inhibit the 
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formation of Vt-mediated actin bundles. Instead, all three MVt CM mutants, enhanced the 




Materials and Methods 
Cloning and generation of expression constructs 
Construct for chicken Vt residues 879-1066 was cloned into pQlinkH vector (Addgene, 
Cambridge, MA), and the C-terminally GFP-tagged construct Vt∆C5-GFP (Vt residues 879-
1061 with C-terminal GFP fusion linked by the sequence “GIGSGSNGSSGS”) was generated 
using ligation-independent cloning in the H6-msfGFP vector (Addgene #29725). Vt∆C5-GFP 
construct encodes an N-terminal TEV (tobacco etch virus) cleavable hexa-histidine tag, the 
linker, and a C-terminal EGFP tag. The N-terminally tagged construct was generated using 
sequence- and ligation-independent cloning, inserting the open reading frame in-frame after the 
GFP (GFP-E892-Vt∆C5, Vt residues 892-1061 with an N-terminal GFP fusion and no linker 
sequence). The codon-optimized sequence of human MVt (residues 858-1134) for bacterial 
expression was synthesized (Geneart), and MVt and MVt∆C5 (residues 858-1129) were sub-
cloned into the 2HR-T vector (#29718), which encodes an N-terminal TEV cleavable hexa-
histidine tag. MVtp (residues 879-1134) was also generated in 2HR-T vector, and this construct 
was designed to lack the proline-rich linker region. Plasmids for MVt cardiomyopathy (CM) 
mutants, A934V, ∆L954, and R975W, were generated using QuikChange site-directed 
mutagenesis kit (Stratagene) and verified by DNA sequencing (Genewiz). All of the Vt and MVt 
vectors contain TEV cleagable hexa-histidine tag. 
Protein expression and purification 
Constructs were transformed into Escherichia coli strain BL21 (DE3) and grown at 37 ºC until 
reaching the optical density of 0.6-0.8 (600nm). Protein expression was then initiated by addition 
of IPTG (0.5 mM for Vt, 1mM for all MVt constructs). Cells were then grown at 18 ºC overnight 
and harvested by centrifugation at 4,500 rpm for 30 min. Cell pellets were resuspended in lysis 
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buffer [20mM Tris, 150 mM NaCl, 5mM imidazole, 2mM β-mercaptoethanol (pH 7.5) for Vt; 50 
mM Tris, 200 mM NaCl, 10mM imidazole, 2mM β-mercaptoethanol (pH 8.0) for MVt]. Cells 
were then lysed by sonication, and the proteins (either Vt or MVt) that remained in the soluble 
fractions were separated by centrifugation at 15,000 rpm for 45 min. Proteins were purified by 
using Ni-NTA agarose beads (Qiagen) as they bound to the beads through His-tag. Wash buffer 
[20 mM Tris, 150 mM NaCl, 60 mM imidazole, 2mM β-mercaptoethanol (pH 7.5) for Vt; 50 
mM Tris, 200 mM NaCl, 25 mM imidazole, 2mM β-mercaptoethanol (pH 8.0) for MVt] was run 
through the column to wash away any impurities bound to the column. Finally, the proteins were 
eluted using elution buffer [20 mM Tris, 150 mM NaCl, 500 mM imidazole, 2mM β-
mercaptoethanol (pH 7.5) for Vt; 50 mM Tris, 150 mM NaCl, 250 mM imidazole, 2mM β-
mercaptoethanol (pH 8.0) for MVt] from the column. His-tags from all proteins were removed 
by dialyzing the eluted volume into TEV cleavage buffer [20 mM Tris, 150 mM NaCl, 50 mM 
imidazole, 2mM β-mercaptoethanol (pH 7.5) for Vt; 50 mM Tris, 200 mM NaCl, 20 mM 
imidazole, 2mM β-mercaptoethanol (pH 8.0) for MVt] overnight at 4 ºC in presence of TEV 
protease. Vt and MVt proteins were then collected by running the dialyzed/TEV-cleaved volume 
over the Ni-NTA beads again. Size exclusion chromatography was used to purify these proteins 
further in gel filtration buffer [10 mM Tris, 200 mM KCl, 10 mM imidazole, 2.5 mM MgCl2, 1 
mM EGTA, and 2mM DTT (pH 7.5)]. Purifed proteins were concentrated between 200-500 µM 
by centrifugation and used for experiments.  
Actin co-sedimentation assays 
The actin binding and bundling properties of individual Vt and MVt WT and CM proteins as 
well as their mixtures were investigated using an adapted actin co-sedimentation assay 
previously reported (114). Monomeric actin (G-actin), purified 
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from rabbit muscle acetonepowder (Pel-Freez Biologicals, Rogers, AR), was stored at − 80 °C in 
storage buffer [50 mM imidazole, 100 mM NaCl, 10 mM MgCl2, 10 mM EGTA, 0.5 mM DTT, 
0.2 mM ATP (pH 7.0)]. Polymerization to filamentous actin (F-actin) was done by diluting and 
incubating G-actin at 100 μM concentration in actin polymerization buffer [10 mM Tris, 200 mM 
KCl, 10 mM imidazole, 2.5 mM MgCl2, 1 mM EGTA, 2 mM DTT (pH 7.5)] at room temperature 
for 30 min. The actin concentrations reported in this work were based on G-actin concentration, 
since the heterogeneity of F-actin polymers made it difficult to quantify F-actin concentrations. 
Vt and MVt variants were also diluted by actin polymerization buffer to prepare 100 μM stocks. 
To assess actin binding, 100 μl samples were prepared containing 10 μM Vt/MVt variants and 10 
or 20 μM actin. The samples were incubated at room temperature for 1 h and then centrifuged at 
100,000 RCF for 30 min. To assess actin bundling, 100 μl samples were prepared containing 10–
20 μM Vt/MVtvariants and 10 μM actin. The samples were incubated at room temperature for 
1 h and then centrifuged at 12,000 RCF for 15 min. For both binding and bundling co-
sedimentation, the supernatant and pellet were separated, resuspended to equal volumes, and 
analyzed by 15% SDS-PAGE. Actin binding properties were calculated by determining the 
fractions of Vt/MVtvariants present in pellets using the densities of the pellet and supernatant 
bands. Actin bundling properties were calculated by determining the fractions of actin present in 
pellets using the densities of the pellet and supernatant bands. Densitometry was performed using 
ImageJ (115). Statistical significances (p values) of the measurements were determined using the 
Microsoft Excel t-Test function. 
Negative-stain transmission electron microscopy 
An aliquot of actin (1 μM) without or with Vt or MVt (10 μM) was incubated in actin 
polymerization buffer [10 mM Tris, 200 mM KCl, 10 mM imidazole, 2.5 mM MgCl2, 1 mM 
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EGTA, 2 mM DTT (pH 7.5)] for 15 min and absorbed directly onto glow-discharged carbon-
coated 400 mesh copper grids for 3 min, and then stained with 2% (w/v) uranyl acetate in water. 
TEM images were obtained using a FEI Tecnai 12 electron microscope at 80 kV and captured on 
a Gatan First Light CCD camera using Gatan Digital Micrograph software (Gatan, Pleasanton, 
CA). F-actin and the indicated Vt ± MVt constructs were mixed in KMEI [50 mM KCl, 1 mM 
MgCl2, 1 mM ethylene glycol bis(b-aminoethyl ether) N,N′-tetraacetic acid (EGTA), 10 mM 
imidazole, 1 mM dithiothreitol (DTT), pH 7.0)] and incubated at room temperature for 15 min. 
Sample (4 μl) was then applied to a glow-discharged continuous carbon grid (Ted Pella) and 
incubated for 60 s. After incubation, the grid was washed with three 100 μl drops of 1% uranyl 
acetate, then blotted to dryness. Images were acquired with the SerialEM package (116) on a 
Tecnai F20 operating at 120 kV with a Gatan Ultrascan 4000 CCD camera. Tiled images with 
20% overlap were acquired at 7800 × magnification, 3 μm underfocus, and 4-fold camera 
binning, corresponding to a calibrated pixel size of 5.7 nm at the specimen level. Stitched images 
were assembled with the “blendmont” program from the IMOD software package (117). This 
work was done by Muzaddid Sarker, former lab member from Campbell lab, in collaboration 
with Lindsey M. Constantini fromJack Griffith’s lab. 
 
F-actin assembly quantification 
Images were thresholded and binarized using ImageJ (115), then segmented into contiguous 
regions of pixels using the built-in “Analyze Particles” plugin, including regions 100–500,000 
pixels in size and with a circularity of 0–0.3. This procedure does not always capture every 
region that an expert user would designate to contain F-actin in every image. However, we find 
its performance superior to both manual segmentation of the images, which requires user 
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decisions on region boundaries and the minimum size of regions, as well as a sliding-box 
quantification (a measure of local density), which is extremely sensitive to noise introduced by 
slight differences in thresholding (data not shown). 
Size measurements of regions were pooled from all images for a given condition, then divided 
into 10,000 equally sized bins per data set and plotted via a normalized cumulative histogram. 
Data were binned and cumulative sums calculated with a python script (available 
at www.github.com/alushinlab/FactinAssemblyQuant) using the function “binned_statistic” 
implemented in SciPy (www.scipy.org). Plots were generated and statistical tests were conducted 
with GraphPad Prism. This work was done by Lin Mei and Santiago Espinosade los Reyes from 
Greg Alushin’s lab.  
 
Molecular dynamics simulation 
Modeling was performed using a DMD package (118-120). The initial structure was obtained by 
extending missing N- and C-termini of MVt (PDB ID: 3JBK) (99) with PYMOL built-in tool to 
include residues 896–1134. The initial structure was relaxed at temperature T = 0.5 with high 
heat exchange coefficient Cex = 10 for 10,000 steps. The temperature unit is kcal/(mol kB).The 
relaxation was followed by replica exchange simulations with 10 replicas (T = 0.330, 0.360, 
0.390, 0.420, 0.450, 0.480, 0.510, 0.540, 0.570, 0.600; Cex = 0.1 for 2 million steps). Replicas 
were exchanged every 1000 steps. To preserve contacts between MVt and actin, we applied 
harmonic constraints to the N, CA, and C backbone atoms of selected residues (R1044, I1045, 
N1048, R1055, T1058, I1059, Q1062, I1065, Q1086, E1089, M1090, H1093, N1094, E1104, 
R1107, E1108, A1111, I1114). These constraints restrict atoms to move within 2A around initial 
positions. All atoms within actin were considered static and were not allowed to move. The 100 
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lowest-energy structures were selected and clustered based on pairwise root mean square 
distance between structures. Two clusters were identified. 
Structures representing the centroids of the two clusters were subject to DMD simulations at two 
constant temperatures T1 = 0.5 kcal/(mol kB) and T2 = 0.55 kcal/(mol kB). For each temperature 
and for each structure, 5 independent simulations were run for 1 million steps with Cex = 0.1. To 
preserve contacts between MVt and actin, we applied harmonic constraints to N, CA, and C 
backbone atoms of selected MVt residues (as described above). All atoms within actin were 






Cryo-EM reconstruction of Vt-actin and MVt-actin complex 
In collaboration with the Alushin lab, we were able to obtain cryo-EM reonstructions of 
of both Vt and MVt in complex with F-actin complex. To circumvent the heterogeneity 
associated with actin bundles formed by Vt, we used a C-terminal truncation mutant (from now 
on referred to as Vt∆C5) that preserves actin binding but disrupts actin bundling (101). I 
expressed and purified the Vt∆C5 and MVt∆C5 proteins used by the Alushin lab for 
reconstructing the cryo-EM structures of Vt-actin and MVt-actin complexes. Both Vt and MVt 
have relatively low affinity for F-actin (~0.5 µM) (103, 121), making it technically challenging 
to fully decorate actin filaments. However, Alushin lab adapted a multi-reference iterative helical 
real-space reconstruction (IHRSR) (122) scheme that they developed for the study of 
heterogeneous microtubule specimens (123). They collected and processed a dataset of 
undecorated F-actin filaments, then subjected either Vt∆C5 or MVt∆C5 -bound dataset to a 
multi-reference IHRSR in EMAN2/SPARX (124, 125) using the sub-stoichiometrically bound 
and unbound models as references. This resulted in Vt∆C5 and MVt∆C5-bound models, in 
which the segments that contributed to these models were selected for further processing using 
FREALIGN (126). This produced an 8.5 Å-resolution reconstruction for Vt-actin complex, and 
likewise produced an 8.2 Å-resolution reconstruction for MVt-actin complex, each showing 






Vt undergoes a structural rearrangement upon actin binding by activating H1-mediated 
bundling via steric mechanism 
In Vt-actin complex reconstruction, we observed density for only four out of the five 
helices within Vt (Fig. 5), possibly due to disengagement of one helix from the bundle upon actin 
binding. Rigid-body docking of the isolated Vt crystal structure (PDB: 1QKR) (127) 
quantitatively supported the interaction pose produced using a DMD model our lab previously 
generated (112), in which helices 4 and 5 constitute the primary actin binding interface. 
Furthermore, we have performed actin binding and bundling co-sedimentation assays with Vt 
M898A, a mutant within H1 that is buried in the pre-bound state, reasoning that it would 
sterically promote H1 release or mediate binding interactions upon being exposed. We found that 
Vt M898A did not affect actin binding but abrogated actin bundling, suggesting that H1 release 
upon actin binding is an important second step to in vinculin activation that mediates Vt-
mediated actin bundling (Fig. 6). This model suggests that helix 1 disengages from the helical 
bundle upon actin binding, which is further supported by our mutagenesis studies and that this 
region is susceptible to proteolytic cleavage upon actin binding by Vt (103).  
In addition to the helix 1 displacement, the rigid-body fit of helices 2-5 showed 
inconsistencies with the density map, including a clash between the N-terminal tip of helix 5 and 
the actin surface (Fig. 5), suggesting that structural rearrangements occur throughout Vt upon 
actin binding. To visualize this conformational transition, Alushin lab performed molecular 
dynamics flexible fitting (MDFF) (128) of Vt residues 917-1047 and actin to generate a pseudo-
atomic model of the interface (Fig. 7). Superposition of the crystal structure of Vt (PDB: 1QKR) 
(127) with the MDFF-derived model reveals a substantial remodeling of the H1 docking site on 





Figure 5. Sub-nanometer-resolution reconstruction of the Vt-actin interface.  
(a) Reconstructions of actin alone (left) and actin decorated with VtΔC5 (right). Actin, light blue; 
Vt, orange. (b) Rigid-body docking of the Vt crystal structure. Helix 1 (H1), which was not 
visualized, is colored magenta. Cryo-EM densities attributed to actin and Vt by docking analysis 
are colored blue and transparent gray, respectively. Difference maps of GFP-E892-VtΔC5–
VtΔC5 (pink) and VtΔC5-GFP–VtΔC5 (green) are displayed as isosurfaces contoured at 15 σ. 
The fusion sites for GFP constructs are labeled and displayed in space-filling representation in 
the same color as the corresponding difference maps. Density tentatively attributed to Vt 
rearrangements is magenta. (c) Colored as in (b), a view highlighting the density on the actin 
surface. Actin 1 is displayed as an electrostatic potential surface map, contoured at ± 10 kBT/e 
(blue, positive; red, negative). (d) Colored as in (b), a view of the Vt H4–H5 helical hairpin, 
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Figure 6. A steric mechanism promotes H1 release to bundle actin. 
(a) Superposition of the MDFF Vt model (orange; view from pointed end) with helices 2–5 of 
the rigid-body docked crystal structure of Vt (PDB ID 1QKR, red). Rearrangement of helices H4 
and H5 to relieve clashes with actin (blue). (b) clash of H1 (magenta) residue M898 with V1024 
in the actin-bound state. (c) Representative SDS-PAGE of high-speed co-sedimentation assay 
demonstrates that Vt M898A retains F-actin binding. Vt M898A, 10 μM. S, supernatant, P, 
pellet. (d) Representative SDS-PAGE of low-speed co-sedimentation assay shows strongly 
impaired actin bundling of Vt M898A. Vt M898A, 10 μM; actin, 20 μM. S, supernatant, P, 
pellet. (e) Quantification of (c). Vt wild-type control. Error bars represent SD, n ≥ 3. N.s., not 
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significant. (f) Quantification of (d). Wild-type. Actin, 20 μM; Vt, 10 μM. Error bars represent 
SD, n ≥ 10. Triple asterisk, p < 0.0001 relative to wild-type control, t-test. Data generated by 





Figure 7. MDFF model of the Vt-actin surface. 
 
The MDFF model (actin 1, light blue; actin 2, dark blue; Vt, orange; ADP, pink) is shown in the 




to the remainder of the bundle (Fig. 6) upon actin binding. We hypothesized that H1 
displacement is necessary for this structural transition to occur as this would generate steric 
clashes between large inward-facing hydrophobic residues in H1 and the rearranged hydrophobic 
core of Vt. Thus, we propose a model in which the need to relieve multiple clashes allosterically 
couples actin binding to H1 release. 
MVt undergoes a similar structural mechanism 
 We also obtained an 8.2 Å-resolution reconstruction for MVt∆C -actin complex (Fig. 4). 
At sub-nanometer resolution, this reconstruction is indistinguishable from the Vt∆C5-bound 
reconstruction. In contrast to a previous negative-stain reconstruction where extra density was 
observed protruding from MVt when compared to Vt (98), rigid-body docking of the MVt 
crystal structure into our sub-nanometer-resolution density map showed that H1’ is displaced 
from the helical bundle when MVt binds actin. This observation is in agreement with the similar 
proteolysis susceptibility reported for MVt H1’ and Vt H1 upon actin binding (103).  
MVt WT does not induce F-actin bundling 
 With this H1’ displacement model, we next investigated the effects of MVt CM mutants. 
However, we first validated our WT Vt and MVt constructs to recapitulate previously reported 
binding and bundling activities (90, 98, 99, 103). I acquired actin co-sedimentation data with Dr. 
Muzaddid Sarker for these studies, while the negative-stain EM images were acquired by Dr. 
Muzaddid Sarker in collaboration with Griffith lab. We first confirmed that there were no 
significant differences between Vt and MVt in actin binding (Fig. 8), and also reproduced 
bundling differences between Vt and MVt proteins. We also determined whether the presence of 
the proline-rich link, that lies adjacent to the tail domain, contributes to higher order actin 





Figure 8. MVt WT and CM mutants exhibit similar actin binding but not crosslinking. 
 
(A) Representative SDS-PAGE results from high speed F-actin co-sedimentation assays in the 
presence of Vt, MVt, or MVtp WT and CM proteins (S, supernatant; P, pellet). (B) 
Quantification of protein present in pellets representing individual sub-populations of Vt, MVt, 
or MVtp constructs bound to F-actin. Error bars represent standard deviation (SD) (n = 3). (C) 
Representative SDS-PAGE results obtained from low-speed F-actin co-sedimentation assays in 
the presence of Vt, MVt, or MVtp WT and CM proteins. (D) Quantification of actin fractions in 
pellets representing sub-populations of F-actin present in bundles or in higher-order assemblies 
induced by Vt, MVt, or MVtp constructs. Error bars represent SD. Statistical significances in 
(n.s.), *p < 0.05, **p < 0.01.  
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containing MVt as MVtp from here on out. While the actin-alone sample showed single, linear 
actin filaments, addition of Vt to F-actin induced crosslinking of filaments into parallel bundles 
as expected, resulting in the formation of thick fibers (Fig. 9). When MVt or MVtp was added to 
F-actin instead of Vt, F-actin bundling was dramatically reduced, with few observable thick 
fibers. This is consistent with previous reports by our group and others that MVt does not induce 
large linear actin bundles like Vt (90, 98, 99, 103), indicating that the MVt insert region prohibits 
actin-induced MVt dimerization. In addition, inclusion of the proline-rich linker (MVtp) has a 
minor, slightly decreased actin bundling effect in vitro. 
MVt CM mutants form higher-order, mesh-like actin assemblies 
We next employed F-actin co-sedimentation assays to examine F-actin binding and 
aggregation activities of MVtp CM mutants, including A934V, ∆L954, and R975W. First, we 
compared the F-actin binding of MVtp WT and CM mutants relative to Vt. Samples containing 
actin (10 or 20 µM) and either Vt or MVt variants (10 µM) were subjected to high-speed 
centrifugation to determine actin binding properties. Under these conditions, the supernatant (S) 
contains unbound Vt or MVt variant while the pellet (P) contains F-actin and bound protein. The 
percent of protein bound to F-actin were determined by SDS-PAGE (Fig. 8) and were quantified 
by ImageJ (115). All MVtp CM mutants, as well as the WT Vt, MVt, and MVtp, showed similar 
binding affinity to F-actin (Fig. 8). From these data, we demonstrate that MVt mutations do not 
impair F-actin binding, consistent with the distal location of the the mutations/deletions from the 
actin binding site.  
After observing that MVtp CM mutants do not affect F-actin binding, we next performed 





Figure 9. MVt exhibits reduced F-actin bundling (crosslinking) compared to Vt. 
 
Negative-stain EM images of actin filaments. Micrographs are acquired at the same 
magnification (scale bar represents 500 nm, shown in the left panel). Crosslinking or bundling of 
actin filaments by Vt generates thick fibers. In contrast, MVt and MVtp do not promote actin 





mutants are altered compared to WT Vt, MVt, and MVtp. With the low-speed centrifugation 
assay, only large cross-linked F-actin and bound proteins are pelleted, while individual actin 
filaments remain in the supernatant. The fraction of actin present in the pellet was quantified to 
determine the amount of higher-order assemblies in these mixtures (Fig. 8). With F-actin alone, 
only ~5% was found in the pellet. However, when Vt was added, almost all of the F-actin 
(~95%) was found in the pellet (Fig. 8). The amount of actin found in the pellet dramatically 
reduced when MVt was added (~26%) and reduced even further when MVtp was added (~13%) 
(Fig. 8). Significantly, there was an increase in the amounts of pelleted actin when MVtp CM 
mutants were added. MVtp A934V increased the amount of pelleted actin to ~29%, ∆L954 to 
~41%, and R975W to 37% (Fig. 8). Even though the low-centrifugation assay is typically used to 
assess F-actin bundling activity, pellets from this assay may contain both thick bundled actin 
fibers but also other large disordered actin structures. Because low-speed centrifugation assay is 
not sufficient to visualize the type of actin assemblies that pellet in the presence of MVt CM 
mutants, we additionally employed negative-stain EM in parallel. The negative-stain EM data 
were found to be consistent with the actin co-sedimentation data (Fig. 10). We observed a 
significant increase in assemblies in the presence of CM mutants MVtp A934V, MVt ∆L954, 
and MVt R975W, with R975W having the most dramatic effect, in accordance with the severity 
of disease caused by this mutation in patients. Examination of the images shows primarily an 
irregular, mesh-like organization of actin filaments, unlike the majority species present as linear 







Figure 10. MVt CM mutants promote disordered, mesh-like F-actin assemblies. 
(A) Stitched negative-stain EM images of F-actin alone and in the presence of WT Vt and MVt 
proteins (bars = 10 μm). Zoomed views of the boxed regions are shown in the bottom panel 
(bars = 1 μm). (B) Stitched negative-stain EM images of F-actin in the presence of MVt or MVtp 
proteins featuring CM mutations (bars represent 10 μm). Zoomed views of the boxed regions are 
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shown (bars = 1 μm). (C) Cumulative plots of F-actin assemblies from the indicated conditions. 
Pairwise comparisons show all distributions to be significantly different (KS test, *p < 0.01). 
N ≥ 10 fields and n ≥ 764 regions were quantified for each condition. F-actin, 0.5 μM; 
Vt/MVt/MVtp constructs, 2.0 μM.  
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MVt WT inhibits Vt-mediated actin bundling 
As mentioned above, while Vt can bundle actin in vitro, MVt lacks the ability to bundle 
actin (90, 98, 99, 103). As metavinculin is co-expressed with vinculin at sub-stoichiometric 
levels under physiological settings, we next investigated higher order actin network organization 
in the presence of both WT Vt and MVt. Our observations that MVt H1′ and Vt H1 are released 
upon actin binding and that H1 mediates Vt's actin bundling activity suggest the following: MVt 
H1′, which differs in sequence from Vt H1, fails to promote MVt dimerization upon actin 
engagement. Interestingly, the H1 sequence is nevertheless present in our MVt construct, 
suggesting that the presence of H1′ inhibits the ability of released H1 to mediate MVt 
interactions. Here, we used MVtp for the purposes of our study. To determine the effect of MVtp 
on Vt-mediated actin bundling, we perfomed low-speed actin centrifugation assay and found that 
adding increasing amounts of MVt to constant amounts of Vt and actin decreased the amounts of 
Vt-mediated actin bundles (Fig. 11). This result suggests that MVtp can inhibit Vt-mediated 






Figure 11. MVt WT inhibits Vt-mediated actin bundling. 
 
(A). Representative SDS-PAGE analysis of differential centrifugation assays of 3.0 μM actin in 
the presence of 3.0 μM Vt and the indicated amounts of MVt. (B). Quantification of (A). Error 
bars represent SD, n=3. Single asterisk, p < 0.05; double asterisk, p<0.01, t-test versus Vt alone. 




MVt CM mutants fail to inhibit Vt-mediated actin bundling 
 Given our finding that addition of WT MVtp at sub-stoichiometric levels relative to Vt 
inhibits Vt-mediated actin bundling, we next examined the effect of MVt or MVtp CM mutants 
on Vt-induced actin bundling. We employed low-speed actin pelleting assays to probe the effects 
of MVt or MVtp CM mutants in comparison to MVt WT, on Vt-induced F-actin assemblies. 
Three sets of actin co-sedimentation data were acquired, with 20 µM actin and Vt:MVtp at 5:5, 
10:10, and 10:5 µM (Fig. 12). In the presence of WT MVt, we observed a proportionate 
reduction of Vt-induced F-actin assemblies as expected. We found ~47-52% F-actin in the pellet 
for Vt:MVt at 1:1 and ~74% F-actin in the pellet for Vt:MVt at 2:1, as opposed to 95% F-actin in 
the pellet for Vt alone. Interestingly, for all 3 MVt or MVtp CM mutatns, almost all of F-actin 
was found in the pellet fractions at both 1:1 and 1:2 ratios. We observed ~87-95% F-actin for 
A934V, ~81-90% for ∆L954, and ~84-89% for R975W. These results indicate that unlike WT 
MVt, MVt or MVtp CM mutants fail to negatively regulate higher-order actin assemblies in the 
presence of Vt.  
 In parallel with the actin co-sedimentation assays, negative-stain EM data additionally 
showed that higher-order assemblies are formed in the presence of both Vt and MVtp variants. 
Consistent with our actin co-sedimentation assays, we find that the presence of MVt WT inhibits 
the bundling activity of Vt at both 1:3 (MVt:Vt) and 1:1 (MVt: Vt) ratios while the presence of 
MVt or MVtp CM mutants dramatically increases the size of F-actin assemblies formed in the 
presence of Vt at both ratios (Fig. 13). The Vt and MVt or MVtp CM mutant negative-stain EM 
data complement the co-sedimentation data and indicate that larger actin assemblies are formed 




Figure 12. MVt CM mutants fail to inhibit Vt-induced F-actin bundling. 
(A–C) Representative SDS-PAGE analysis of low-speed F-actin co-sedimentation assays 
incubated with Vt in the presence of MVtp WT protein (labeled as MVtp) or MVtp CM mutants 
at indicated concentrations (S, supernatant; P, pellet). (D) Quantification of the actin present in 
pellets representing higher-order F-actin assemblies that include F-actin bundles in case of Vt. 
Error bars represent standard deviation (SD) (n = 2, 5 replicates for each n). Statistical 
significances in panel D are indicated by the following: non-significant (n.s.), *p < 0.05, 




Figure 13. MVt CM mutants aggregate Vt-induced actin bundles. 
(A) Stitched negative-stain EM images of F-actin in the presence of Vt + WT or CM mutant 
MVt(p) at Vt to MVt(p) ratio of 3:1 (bars=10 μm). Zoomed views shown in the bottom panel 
(bars=1 μm). F-actin 0.5 μM, Vt 3.75 μM, and MVt(p) 1.25 μM. (B) Stitched negative-stain EM 
images of F-actin in the presence of Vt + WT or CM mutant MVt(p) at Vt to MVt(p) ratio of 1:1 
(bars=10 μm). Zoomed views shown in the bottom panel (bars=1 μm). F-actin 0.5 μM, Vt 
2.5 μM, and MVt(p) 2.5 μM. (C) Cumulative plots of F-actin assemblies in the presence of Vt to 
MVt(p) at ratio of 3:1. (D) Cumulative plots of F-actin assemblies in the presence of Vt to 
MVt(p) at ratio of 1:1. (KS test, p < 0.0001) in panels C and D.  
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DMD suggests that MVt-specific insert region forms an additional sub-domain upon actin 
binding 
 To gain further structural insight into rearrangements associated with MVt-actin 
interaction, we worked in collaboration with the Dokholyan lab. Using a single MVt including 
residues 896-1134 bound to an actin homodimer (F-actin) as the starting point (PDB: 3JBK) 
(99), DMD simulations were performed using replica exchange for 2 million steps. One hundred 
minimal energy structures were selected and clustered. Through this method, two clusters were 
identified (Fig. 14), with different N- and C-termini conformations. While structures from the 
first cluster have tightly intertwined N- and C- termini (Fig. 14), structures from the second 
cluster show the C-terminus interacting with the surface of F-actin (Fig. 14). Both clusters form a 
new additional structural sub-domain protruding outwards from F-actin. The structures were 
subjected to DMD simulations and appeared to be stable throughout the simulations, further 
supporting the protruding MVt sub-domain formation upon actin engagement. Therefore, we 
hypothesize that this sub-domain mediates unique biological functions of MVt relative to Vt, 
such as the inability to produce F-actin bundles and the ability to suppress Vt- mediated F-actin 
bundling. As the MVt CM mutants fail to inhibit Vt-induced actin bundling, we hypothesize that 
the CM mutations within the insert impair formation of the protruding structure. Further 
supported by our simulations studies, we predict that the MVt CM mutations destabilize the 





Figure 14. Actin binding to MVt may induce a formation of protruding structure. 
Actin binding to MVt may induce a higher-order structural element that prevents F-actin 
bundling. DMD simulations identify two distinct MVt–actin clusters. In contrast to Vt, actin 
binding to MVt induces a protruding sub-domain. Representative MVt and F-actin models show 
that additional structure is formed between N-terminus, insert, and C-terminus in the first cluster 
(A) and between N-terminus and insert in the second cluster (B). MVt residues mutated in CMs 
(A934, L954, R975) are colored red. Point mutations A934V and R975W cause an increase in 
∆∆G (D) and thus destabilize the folded sub-domain. These findings suggest that MVt CM 






 Using cryo-EM, molecular modeling, and complimentary biochemical techniques, we 
have produced detailed models of the critical interactions between F-actin, vinculin, and 
metavinculin. First, our cryo-EM reconstructions of Vt-actin and MVt-actin show that both H1 
and H1’, respectively, are unfurled upon binding to F-actin. This finding adds an additional layer 
to the vinculin activation mechanism. After the interaction between Vh and Vt is disrupted, H1 
must also be disengaged to license the Vt actin interaction. Although our data do not discriminate 
between H1 released followed by actin binding or vice versa, the steric incompatibility between 
the H1-docked state and the actin-bound state and NMR data suggesting that H1 undergoes 
conformational exchange in the isolated Vt (129) support the former model. Furthermore, 
vinculin sustains substantial tensile forces in adhesions in vivo (77), and a previous study 
demonstrated that vinculin is, on average, oriented along the dorsal-ventral axis of an adherent 
cell with the Vh domain closer to the ventral surface (27). These data suggest that a vinculin 
molecule bound to both talin via Vh and actin by Vt will experience tensile forces in geometry 
that will favor the undocking of H1 from the Vt bundle. Based on this geometry, we hypothesize 
a mechanism where vinculin can reinforce adhesion in response to force. We speculate that if H1 
is in equilibrium between the docked and undocked states, the presence of tension will favor H1 
undocking and by extension, actin binding and bundling, further increasing the adhesion-
cytoskeleton linkage (Fig. 15). 
 Next, we found that MVt suppressed actin bundling by Vt, suggesting that metavinculin 
may tune actin bundling by vinculin in highly contractile tissues. It is interesting to note that 
vinculin is ubiquitously expressed in all cell types but metavinculin, only other vinculin isoform, 





Figure 15. Model of vinculin activation and tension reinforcing actin engagement. 
Upon entering an adhesion, the interaction between Vh (green) and Vt (orange) is broken by 
engaging multiple binding partners (not diagrammed). The linkage between Vh and the plasma 
membrane (black line) occurs through multiple layers of binding partners (e.g. talin, integrin, 
schematized as a broken line, not to scale). H1 (magenta) must undock from the Vt bundle for Vt 
to engage actin. After actin binding and H1 release, Vt is capable of bundling actin (note: the 
detailed structure of the actin-induced Vt dimer structure remains unknown; magenta circle 
indicates an interaction). In this configuration, tension across the vinculin molecule will prevent 





and metavinculin expression increases corresponding to the contractile load on the tissue (83, 
84). Cardiomyocytes especially undergo rapid contraction and expansion as the heart beats. 
Based on these observations, we suggest that the presence of vinculin alone may cause the heart 
muscle to become stiff due to a large network of thick F-actin fibers, preventing the necessary 
contractile properties. Co-expression of metavinculin may be therefore necessary to regulate the 
vinculin-actin bundling so that cardiac cells remain flexible and functional. This hypothesis is 
further supported by our finding that MVt CM mutants are dysfunctional in suppressing the actin 
bundling by Vt.  
 We speculate that Vt H1 could mediate bundling contacts between Vt molecules after 
actin binding and further suggest that released H1’ and the upstream disordered sequence in MVt 
are important for MVt’s inhibitory activity by unknown mechanisms. As MVt CM-associated 
point mutants are located within the insert, either within H1’ or very close to the N-terminus of 
H1’, but distal from the direct actin binding regions of H2-H4, we hypothesize that these 
mutations would compromise MVt’s regulation of Vt-mediated actin bundling without disrupting 
actin binding. Our results are in support of this model and accordingly, through actin co-
sedimentation assays and negative-stain EM, we found that all of the MVt CM mutants have a 
defect in regulating Vt’s actin bundling activity, in contrast to WT MVt, but are not impaired in 
actin binding. Mechanistically, we propose a steric occlusion model for metavinculin’s ability to 
negatively regulate vinculin-induced actin bundling in sub-stoichiometric amounts, mediated by 
the formation of MVt sub-domain upon actin binding. Our simulation studies suggest that MVt 
insert coordinates the folding of a protruding globular sub-domain upon actin binding, as this 
induces a release of H1’ and upstream sequences from the rest of the MVt helix bundle. While 
the detailed structure of the Vt-dimer that promotes 3D actin bundles is unknown and remains an 
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important subject for future studies, electron tomographic studies of Vt-induced 2D F-actin 
arrays on lipid monolayers suggested that filaments are very tightly apposed when cross-linked 
by Vt (110). We therefore propose that MVt sub-domain acts as a steric block that prevents 
another actin-bound Vt from coming in closer range, which would then prevent Vt-mediated 
actin bundling (Fig. 16).  
Further in support of this model, our computational studies demonstrate that MVt CM 
mutants destabilize the MVt sub-domain formation, which would remove the steric block to 
actin-bound Vt and promote actin bundle formation (loss of function). However, it is important 
to note that the MVt sub-domain steric block model can only partially explain the effect MVt 
CM mutants have on actin network reorganization. Though not obvious through actin co-
sedimentation assay, negative-stain EM results revealed that all MVt CM mutants had a gain-of-
function effect where they induced an increase in the formation of higher-order F-actin 
assemblies (Fig. 10), with a disordered, mesh-like morphology. Also, our studies suggest that the 
MVt CM mutants additionally drive the coalescence of Vt-induced bundles into aberrantly large 
assemblies (Fig. 13). We hypothesize that MVt CM mutants stimulate aggregation of actin 
through the MVt insert region that would be exposed due to defects in sub-domain folding (Fig. 
16).  
While our biochemical and structural studies have focused on the three main components, 
Vt, MVt, and F-actin, vinculin is a scaffold protein that interacts with a number of ligands under 
physiological settings. Hence, the presence of metavinculin in conjunction with vinculin may not 
only affect their interactions with actin and each other, but also with other ligands. This is a 
complicated problem that will require additional studies, as these additional interactions could 





Figure 16. Model for how MVt WT and CM mutants affectVt-induced actin bundle. 
Model for inhibition of Vt-induced F-actin bundle by MVt WT but failure of that by MVt CM 
mutants. (A) Release of H1 upon F-actin engagement enables Vt dimerization, thus resulting in 
parallel F-actin bundle formation. (B) An additional protruding structural sub-domain formed by 
the insert and displaced H1 at the N-terminus of MVt WT blocks homo- or hetero-dimer 
formation with Vt, thus preventing F-actin bundling. (C) The protruding sub-domain is 
destabilized by the CM related mutations in MVt CM , resulting in disordered F-actin assemblies 





CHAPTER 3 – Vinculin and Metavinculin Exhibit Distinct Effects on Focal Adhesion 
Properties, Cell migration, and Mechanotransduction 
Introduction 
Vinculin (Vcn) is an essential, ubiquitously expressed cytoskeletal protein that localizes to 
focal adhesions (FAs) and adherens junctions (73, 130). It acts as a scaffold to link transmembrane 
proteins to actin filaments and plays a key role in cell adhesion, motility, and force transmission 
between cells and the cell-matrix interface. Vcn knockout mouse embryos do not survive past E10 
and exhibit cardiac and neural tube developmental defects (43). Additionally, Vcn null murine 
embryonic fibroblasts (MEFs) exhibit a more rounded morphology, increased motility (43, 44) 
and resistance to apoptosis and anoikis (45). At the molecular level, Vcn is comprised of a large 
~90 kD head domain, a flexible proline-rich linker, and a tail domain (46).  As part of its scaffold 
function, Vcn engages a number of cytoskeletal and adhesion proteins as well as 
phosphatidylinositol 4,5-bisphosphate (PIP2). The Vcn head interacts with talin at FAs, α-catenin 
at cell-cell junctions, and α-actinin at both cellular locations (47-49, 131). The proline-rich linker 
that connects Vcn head to Vcn tail can bind to a number of cytoskeletal proteins including VASP, 
vinexin, CAP/ponsin and the Arp2/3 complex (50-53). Vcn tail directly binds to filamentous actin 
(F-actin) (54), PIP2 (55), paxillin (132, 133), and Raver1 (56). Autoinhibitory interactions between 
the Vcn head and tail promote a closed inactive state, which obscures ligand-binding sites available 
to other interacting proteins (46).  Although mechanisms of activation are not fully understood, 
it is believed that engagement of talin or α-catenin to Vcn head in conjunction with binding of 
additional ligands such as actin (47, 72, 73), post-translational modifications (74), and/or 
57 
 
mechanical tension (75-78), promote Vcn activation and scaffolding function by exposing multiple 
ligand binding sites. 
Metavinculin (MVcn) is a larger splice isoform of Vcn that is selectively expressed in 
smooth and cardiac muscle cells and at low levels in platelets (42, 79, 81).  MVcn is expressed 
at sub-stoichiometric levels relative to Vcn (9-42%), and its expression correlates with the elevated 
contractile needs of these muscle cells (83, 84).  Complete knockout or heterozygous inactivation 
of the Vcn gene is associated with dilated cardiomyopathy in mice (93, 94), while reduced MVcn 
expression is also associated with dilated cardiomyopathy (DCM) and disorganized intercalated 
disc structures in humans (89). Point mutations in MVcn have also been identified in patients with 
DCM and hypertrophic cardiomyopathy (HCM) (89-91). While A934V and ∆L954 MVcn 
mutations are associated with DCM (90), an R975W mutation has been identified in patients with 
both DCM and HCM (91).  Both DCM and HCM are diseases of the myocardium that diminish 
blood flow within the heart due to reduced force transmission.  
 
MVcn and Vcn structurally share the same head domains (95, 96); however, their tail 
domains differ. Vcn tail domain possesses an N-terminal strap followed by a 5-helix bundle and 
C-terminal hairpin (46), while the MVcn tail domain contains an additional exon that encodes a 
68 amino acid insert (79). While MVcn tail has a 5-helix bundle fold similar to Vcn tail, the 
sequence that makes up the helix 1 (H1) and strap of Vcn tail is displaced in the MVcn tail by 
homologous sequences, which we term H1’, contained within this insert (95) (Fig. 3). Similar to 
Vcn tail domain, MVcn tail directly binds F-actin (95, 98, 99) but unlike Vcn tail domain, MVcn 
tail does not bundle filamentous actin into higher order structures in vitro (90, 98-100). However, 
as MVcn and Vcn are co-expressed in muscle tissues (42, 79, 84), it is likely that they coordinately 
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regulate actin filament organization.  In fact, we and others have previously observed that the 
presence of MVcn tail at sub-stoichiometric ratios impairs Vcn tail-mediated F-actin bundling (99, 
103), suggesting that MVcn tail may negatively regulate Vcn tail-mediated actin bundling. 
 
While these differences in the ability of MVcn tail and Vcn tail to independently and 
coordinately reorganize actin networks have been observed in vitro, the field currently lacks a 
comparison of MVcn and Vcn in a cellular context. To investigate whether these two isoforms 
regulate distinct cellular functions, we stably expressed either MVcn or Vcn in a Vcn-null MEF 
background and compared FA properties, cell migration, and cell reinforcement to external force. 
Though we initially sought to use smooth muscle or cardiac cells as a system of comparison, the 
difficulty in maintaining and controlling for MVcn expression in cell culture prevented us from 
using those cells. In smooth and cardiac muscle cells, MVcn loses expression in cell culture unless 
the contractile environment is mimicked properly (84). On the other hand, the Vcn-null MEF 
background allowed us to manipulate the expression levels of either Vcn or MVcn. We find that 
MVcn expression can fully rescue cell area and partially rescue FA number per cell.  However, 
compared to Vcn-expressing cells, MVcn expression leads to larger individual FA area, faster cell 
migration, and decreased cell stiffening in response to external force. Our results suggest both 




Materials and Methods 
Cell Culture 
 
WT MEFs and Vcn-null MEFs were a gift from Dr. Brent Hoffman (Duke University), originally 
from Drs. Ben Fabry and Wolfgang Goldmann of the Erlangen Biophysics Group at the University 
of Erlangen-Nuremberg in Germany (134). Human embryonic kidney (HEK) 293T cells were a 
gift from Dr. Channing Der at UNC. All cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM; Invitrogen) supplemented with 10% fetal bovine serum (Sigma) and antibiotic-
antimycotic solution (Sigma). They were grown in a 37°C incubator with 5% CO2.  
 
DNA Constructs and Generation of Stable Cell Lines 
 
mEmerald-Vinculin-23 was a gift from Michael Davidson (Addgene plasmid #54302; 
http://n2t.net/addgene:54302; RRID: Addgene_54302). mRFP-C1 was a gift from Robert 
Campbell & Michael Davidson & Roger Tsien (135) (Addgene plasmid #54764; 
http://n2t.net/addgene:54764; RRID: Addgene_54764). Human MVcn gene, a generous gift from 
Dr. Tina Izard, was cloned into RFP-C1 between SalI and ApaI restriction sites. mEmerald-tagged 
full-length human Vcn construct (1-1066) and mRFP-tagged full-length human MVcn construct 
(1-1134) were then subcloned into the pBabe-puro vector. Both fusion proteins were inserted using 
the restriction enzyme sites NgoMIV and SnaBI. Using the pBabe retroviral system to generate 
stable cell lines, we first generated retroviruses by transfecting HEK 293T cells with either the 
pBabe-puro mEmerald-Vcn or mRFP-MVcn constructs and the retrovirus packaging vector pCL-
10A. pBabe-puro and pCL-10A vectors were gifts from Dr. Channing Der (UNC-Chapel hill). 
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After 48 hours, the viruses were harvested and used to infect Vcn-null MEFs using 8 µg/mL 
polybrene. Vcn-null MEFs were infected for 24-48 hours and those expressing either mEmerald-
Vcn or mRFP-MVcn proteins were selected with 7.5 µg/ml puromycin for a week. After the cells 
were kept under the selection pressure at 5 µg/ml puromycin for about 3 weeks, they were sorted 
for expression by flow cytometry. Expression levels of both mEmerald-Vcn and mRFP-MVcn 
were verified by Western blot analysis using anti-mouse vinculin antibody (Sigma), which 
recognizes both Vcn and MVcn, and HRP-conjugated anti-mouse IgG (Jackson). Actin bands were 




To select for established stable cells with consistent expression of mEmerald-Vcn or mRFP-MVcn, 
we sorted the established stable cells using a MoFlo XDP cell sorter from the UNC Flow 
Cytometry Core Facilty and chose cells with equivalent expression similar to physiological levels 
of Vcn. To ensure that any phenotypic differences between mEmerald-Vcn or mRFP-MVcn 
expressing cells were comparable, we tested the sorted cell populations for expression level via 
Western blot (Fig. 17A) and chose cells with equivalent expression of mEmerald-Vcn and mRFP-
MVcn equal to endogenous levels of Vcn in WT MEFs as a guide. The resulting stable cell lines 







Quantification of Focal Adhesion Area and Number per Cell 
 
Prior to FA analysis, cells were serum-starved in DMEM media supplemented with 0.5% 
delipidiated bovine serum albumin (BSA) and antibiotic-antimycotic solution. Cells were then 
trypsinized, resuspended in this same media, and rotated at 37ºC for 2 hours before plating. Cells 
were seeded on glass coverslips coated with 50 µg/ml of FN and allowed to spread for 2 hours. 
Cells were then washed with phosphate-buffered saline (PBS), fixed in 3.7% formaldehyde for 15 
min, and permeabilized in 0.2% TritonX-100 for 10 min in room temperature. Fixed cells were 
blocked with 5% BSA for 30 min at room temperature, and incubated with a mouse monoclonal 
anti-paxillin antibody (BD Transduction laboratory) for 1 hour. After washing with PBS, cells 
were stained with appropriate secondary antibody (either goat anti-mouse Alexa Fluor 488 (for 
mRFP-MVcn-expressing cells), or goat anti-mouse Alexa Fluor 568 (for mEmerald-Vcn-
expressing cells) (Invitrogen) for an additional hour. Immunofluorescence images were then taken 
with a Zeiss Axiovert 200M microscope equipped with a Hamamatsu ORCA-ERAQ digital 
camera and 63x oil objective. A previously reported method (136) was adapted and used to identify 
and quantify the properties of paxillin-stained FA. This method applies a high pass filter to the 
images and a user-specified threshold to identify FA. Thresholded objects smaller than 10 pixels 
and larger than 200 pixels were excluded from analysis. FA number and size (area) was quantified 





Real-time Cell Analysis (RTCA) and cell spreading 
 
The RTCA xCELLigence system (Acea Biosciences) uses electrical impedance to monitor the 
status of cells grown on micro-electrode coated plates (137). With sparsely plated cells, changes 
in impedance reflect cell coverage of the substrate, i.e. cell attachment and spreading, reported as 
cell index (CI). Prior to seeding, cells were serum-starved in DMEM media supplemented with 
0.5% delipidated BSA and antibiotic-antimycotic solution. Cells were then trypsinized, 
resuspended in this same media, and rotated at 37ºC for 2 hours before being plated on 50 µg/ml 
FN-coated E-plate 16 wells. Cell Index was recorded at an interval of 15 sec for the first 4 hours, 
and subsequently at an interval of 3 min for the next 6 hours. Experiments were repeated 4 
independent times with at least triplicates per sample. The slope of the RTCA trace was quantified 
from a trend line determined in Excel from data points between 0-2 hours post cell seeding. 
 
To complement the RTCA data, cell area was also quantified by immunofluorescence. For the 
purposes of imaging, after plating for 2 hr, cells were fixed and incubated with either Alexa Fluor 
488-phalloidin (for mRFP-MVcn cells) or Alexa Fluor 568- phalloidin (for mEmerald-Vcn cells) 
(Invitrogen) for 1 hour. Cell area was quantified using ImageJ (115). Resulting data were 
represented as mean ± S.E.M. 
 
Random Cell Migration Assay 
Glass-bottomed culture dishes (MatTek Corp) were coated with 10 µg/ml FN at 37°C for 1 h. Cells 
were plated overnight before imaging. Cells were imaged at 37°C with 5% CO2 with a 10× 
objective on an Olympus VivaView FL microscope (Hooker Imaging Core at UNC) for 11 hours 
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with 15 min intervals. Single cell tracking was manually performed in ImageJ (115) using the 
“Manual Tracking” plugin, in which cells are tracked based on the approximate centroid location 
over time. Only single cells were tracked and data was discarded if the cell experienced cell 
division, cell death, a collision event (with another cell or debris), or if it migrated out of the field 
of view. To obtain velocity and persistence values, raw tracking data were analyzed with the 
“Chemotaxis Tool” plugin (Ibidi) in ImageJ (115). 
Focal Adhesion Assembly and Disassembly 
TIRF images were collected on an Olympus IX81-ZDC2 inverted microscope equipped with a 
UAPON 100x/1.49NA DIC TIRF objective (Olympus), an automated XYZ stage (Prior) and an 
Andor iXon EM-CCD. Images were procured using the Metamorph acquisition software with 110 
nm laser penetration depth. Time-lapse imaging was performed with a stage top incubator that 
maintained humidity, 37°C and 5% CO2 (Tokai Hit). Images were acquired every 15 sec for 30 
minutes. Acquired images were further processed in ImageJ (115) to subtract background noise 
and to correct for photobleaching. A previously reported method (136) was used to identify and 
quantify the assembly and disassembly rates of the tracked focal adhesions within a single cell. 
This method applies a high pass filter to the images and a user-specified threshold to identify FA. 
Thresholded objects smaller than 10 pixels were excluded from analysis. All adhesions within a 




Three-dimensional force microscopy (3DFM) (138), a magnetic tweezer system, was used to apply 
consistent pulses of local 60-100 piconewton force to FN-coated magnetic beads, which were 
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allowed to adhere to cells. Tosyl-activated magnetic dynabeads (2.8 um, Thermofisher) were 
washed with PBS and incubated overnight with FN at 37ºC. After three washes with PBS, the 
beads were pipetted up and down vigorously to break up the aggregates and incubated with the 
cells for 20 minutes. Cells with 1 bead per cell were chosen for analysis. Constant force was 
applied for 5 sec intervals followed by 10 sec relaxation; this pattern was repeated for a total of 5 
pulses. Upon the application of force, bead displacements were recorded with high-speed video 
camera (Jai Pulnix, San Jose, CA). Beads were tracked using Video Spot Tracker software (139). 
The 3DFM system was calibrated prior to experiments using a fluid of known viscosity. We used 
2.5 M sucrose as a fluid of known viscosity, which has a viscosity of 140 mPA-sec. Beads showing 
less than 10 nm of displacement (detection threshold for the 3DFM) were discarded for analysis. 
Custom Matlab scripts were used to calculate creep compliance, Jmax, also known as the deformity, 




, where rmax is the bead displacement due to the magnetic force F and α is the radius 
of the bead. Bead displacements were normalized to the bead displacement for Pulse 1 for each 
cell type and experiment and reported as mean ± S.E.M.  
 
Statistical Analyses 
Unpaired 2-tailed t-test was used for comparisons between two means. One-way ANOVA 
followed by Tukey post hoc was performed for multiple comparisons. All data were presented as 
mean ± S.E.M. unless otherwise noted. Statistical significance was set at *P<0.05; **P<0.01; 
***P<0.001; P>0.05, not significant (n.s.). 
Quantification of FA number per cell and FA area. 
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One-way ANOVA followed by Tukey post hoc for FA number per cell was used to analyze 
significance. Unpaired 2-tailed student t-test was used for FA area analysis as one-way ANOVA 
with Tukey post hoc could not be performed because the number of groups is greater than 100. 
Real-time Cell Analysis (RTCA) and cell spreading.  
Cell Index of all cell types were analyzed using one-way ANOVA followed by Tukey post hoc at 





MVcn-expressing cells have fewer but larger FAs compared to Vcn-expressing cells 
To establish a systematic comparison between Vcn and MVcn, we stably expressed either 
mEmerald-Vcn or mRFP-MVcn in Vcn-null mouse embryonic fibroblasts (MEFs). Because 
fibroblasts do not express endogenous MVcn, Vcn-null MEFs lack both endogenous Vcn and 
MVcn, providing a cell line that enables comparison of phenotypes associated with exogenously 
expressed Vcn or MVcn. To ensure similar expression levels of Vcn and MVcn, we used flow 
cytometry to select cells with Vcn or MVcn expression at levels equivalent to endogenous Vcn 
expressed in wildtype MEFs (Fig. 17A and Fig. 18). We first confirmed that exogenously 
expressed Vcn and MVcn are both recruited to FA in the stable re-expressing cell lines (Fig. 17B). 






Figure 17. MVcn-expressing cells have larger but fewer FAs compared to Vcn-expressing 
cells.  
 (A) Western blot shows the expression level of either Vcn or MVcn in Vcn null MEF 
background. Both expression levels are equivalent to endogenous Vcn expression in WT MEFs. 
(B) Fluorescent images of WT MEF, Vcn-null parent MEF cell line, exogenous Vcn-expressing, 
and MVcn-expressing Vcn-null MEFs stained for paxillin and showing expression of either 
fluorescently-tagged Vcn or MVcn. Scale bar = 10 µm. FA number (C) and overall FA area per 
cell (D) were quantified. Graphs represent data pooled from 4 independent experiments (n ≥ 100 





Figure 18. mEmerald-Vcn and mRFP-MVcn cells were sorted for expression using flow 
activated cell sorting (FACS). 
For all panels, the top left figure represents population gated for cells of interest, top right figure 
represents population gated for doublet discrimination, and the bottom figure represents 
populations sorted based on the fluorescence intensity. Sort data for (A) Vcn-null MEF as non-
fluorescent control for mEmerald-tag. (B) Vcn-null MEF as non-fluorescent control for mRFP-
tag. (C) mEmerald-Vcn cell population. (D) mRFP-MVcn cell population. Population of high-
expressing mRFP fluorescence from gate R5 used for experiments for (C) and (D).  
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As FAs are macromolecular structures that regulate cell adhesion, motility, and force 
response and transmission, we characterized FA properties of cells expressing either MVcn or 
Vcn, and compared them to the Vcn-null parent cell line. We employed immunofluorescence to 
quantify the mean FA area and the number of FA per cell using paxillin staining as a marker for 
FAs. The FAs of MVcn-expressing cells had larger areas but were fewer in number than the FAs 
of Vcn-expressing cells (Fig. 17C-D). The mean FA area in MVcn-expressing cells was ~37% 
larger relative to that of Vcn-expressing cells (Fig. 17C; Table 1). However, MVcn-expressing 
cells had 37% fewer FA per cell compared to Vcn-expressing cells (Fig. 17D; Table 1). Overall, 
the FA properties of MVcn-expressing cells were more similar to the Vcn-null parent cells: FA 
size was not significantly different between MVcn-expressing cells and Vcn-null cells, although 
MVcn-expressing cells had slightly increased number of FAs per cell (30% increase) (Fig. 17C-
D; Table 1). Intriguingly, we have previously shown that a carboxyl-terminal deletion variant of 
Vcn that is defective in actin bundling shows similar FA properties to MVcn-expressing cells 
(101).  Furthermore, our observations that Vcn-expressing cells form smaller but more FAs per 






Table 1. Quantificatied values of experimental results. 
 
Experiment Vcn null Vcn MVcn 
FA area (µm2) 1.041±0.007 0.760±0.004 1.039±0.006 
FA number per cell 103±3 212±6 134±4 
Cell area (µm2) 818±27 1457±38 1481±41 
Cell spreading rate (RTCA slope) 0.04 0.12 0.13 
Cell Index (CI) at 2 hours 1.04±0.01 1.13±0.01 1.15±0.01 
Velocity (µm/min) 0.84±0.03 0.29±0.01 0.52±0.02 
Persistence 0.39±0.02 0.55±0.02 0.66±0.01 
FA assembly rate (min-1) N/A 0.139±0.004 0.110±0.004 





MVcn fully rescues cell area to the same extent as Vcn in Vcn-null MEFs 
Given the differences in FA number and FA area observed between Vcn- and MVcn-
expressing cells, we next investigated differences in cellular phenotype. Vcn deletion has 
previously been shown to significantly decrease cell size (44, 112), thus we examined whether re-
expression of Vcn or MVcn could rescue cell area. Vcn-null, Vcn-expressing, and MVcn-
expressing cells were stained with phalloidin to mark cell area (Fig. 19A). Both Vcn- and MVcn-
expressing cells had comparable cell areas that were significantly increased over Vcn-null cell area 
by 78% and 81%, respectively (Fig. 19B; Table 1). Moreover, Vcn- and MVcn-expressing cells 
did not show significant differences in cell aspect ratios (Fig. 20).  Upon finding that both Vcn 
and MVcn can rescue cell area in Vcn-null MEFs, we next quantified cell spreading on fibronectin 
(FN) using a real-time cell analyzer (RTCA) xCELLigence system. Compared to Vcn-null, cells 
expressing Vcn or MVcn had 10% higher Cell Index (CI), which represents electrical impedance, 
indicating increased cell area (Fig. 19C-D). Additionally, the slopes of these traces provide real-
time information on cell spreading rate. Based on this, Vcn-null cells have a slower spreading rate 
compared to both Vcn- and MVcn-expressing cells (~66%; Table 1). Thus, both Vcn and MVcn 
can fully rescue the decreased cell area of Vcn-null MEFs and show comparable cell spreading 





Figure 19. MVcn rescues decreased cell area in Vcn-null MEFs. 
(A) Stable fluorescently-tagged Vcn or MVcn expression in Vcn-null MEFs, co-stained with 
phalloidin, to allow cell area quantification. WT MEFs and Vcn-null MEFs stained with 
phalloidin and Vcn antibody are shown for comparison. (B) Cell area quantification. (n ≥ 150 
cells per cell type, data pooled from 3 independent experiments; ***, p<0.001). (C) 
Representative real-time impedance traces from the RTCA xCELLigence system, measuring 
impedance every 15 s for the first 4 hours, and then every 3 min for the next 6 hours. Cell Index 
(CI) represents electrical impedance. First 8 hours are shown. CI is higher in cells expressing 
Vcn and MVcn compared to Vcn-null MEFs, indicating greater cell spreading. (D) 
Quantification of CI at 2 hours after seeding cells. Data pooled from 4 independent experiments 




Figure 20. Cell aspect ratio for all cell types. 
 





MVcn-expressing cells have faster migration velocity and higher persistence than Vcn-
expressing cells 
Vcn plays a key role in regulating cell motility as deletion of Vcn increases cell motility 
and random migration in 2D environments (43, 44, 134). We assessed whether MVcn could restore 
a normal cell migration phenotype in the Vcn-null cell background. For Vcn-null, Vcn-, and MVcn-
expressing cells, we monitored individual cell migration tracks every 15 minutes, manually 
tracking single cells and calculating both velocity and persistence via ImageJ (115). Cell migration 
tracks show distinct migration paths for each cell type, with MVcn-expressing cells displaying 
longer migration tracks compared to the cells re-expressing Vcn (Fig. 21). 
 
Cell migration velocity and cell persistence of the three cell types were also quantified. 
MVcn-expressing cells migrated faster than Vcn-expressing cells by ~78%, while Vcn-null cells 
migrated faster than either Vcn- or MVcn-expressing cells by ~184% and ~60%, respectively (Fig. 
21B; Table 1). Finally, we found that Vcn-expressing cells were more persistent than Vcn-null 
cells (~40%; Fig. 21C; Table 1), consistent with observations from other groups (43, 134, 140). 
Unexpectedly, MVcn-expressing cells were ~20% more persistent than Vcn-expressing cells and 





Figure 21. Random cell migration analysis shows enhanced migration velocity and higher 
persistence of migration for cells expressing MVcn compared to Vcn-expressing cells. 
(A) Representative cell tracks plotted for n>50 cells. (B) Quantification of random migration 
velocity. (C) Quantification of directional persistence. Data pooled from 3 independent 





Vcn has faster assembly and disassembly rates at FA than MVcn 
Focal adhesion assembly rate and turnover are highly dynamic events underlying cell migration 
(130).  Because the difference in average FA area and FA number per cell between Vcn- and 
MVcn-expressing cells suggested a potential difference in FA turnover, we examined FA 
dynamics of Vcn- or MVcn-expressing cells. Using total internal reflection fluorescence (TIRF) 
microscopy, we followed all of the adhesions within a single cell to quantify assembly and 
disassembly rates (Fig. 22; Table 1). Vcn-containing FAs assembled at a faster rate (~26%) 
compared to MVcn-containing FAs (Fig. 22B; Table 1). Likewise, Vcn-containing FAs showed a 
faster disassembly rate (~34%) compared to MVcn-containing FAs (Fig. 22C; Table 1). The plots 
of fluorescence intensity with respect to time are also shown (Fig. 23). To ensure that the difference 
in fluorophores between Vcn and MVcn was not a contributing factor in measurements of FA 
assembly and disassembly rates, we tagged both proteins with the same mEmerald fluorophore 
and found the results to be consistent (Fig. 24). These results indicate that Vcn-containing FAs 
undergo faster FA turnover compared to MVcn-containing FAs, consistent with the previous 





Figure 22. Focal adhesion assembly and disassembly rates are higher for Vcn-expressing 
cells compared to MVcn-expressing cells. 
(A) Representative time-lapse image sequences of Vcn-null MEFs stably expressing either 
mEmerald-Vcn or mRFP-MVcn migrating on 10 µg/ml FN. Images (shown in grayscale) are 
taken every 15 sec. Green outlines (generated by focal adhesion analysis program) show 
individual FA. Scale bar = 10 µm. Graph of average rate constants of FA assembly (B) and 
disassembly (C) from FAs in each cell type. Data pooled from 3 independent experiments (n ≥ 




Figure 23. Average and representative assembly and disassembly curves at FA. 
All panels show fluorescence intensity plotted with respect to time as FAs either assembled or 
disassembled. For (A)-(D), all shaded areas indicate S.E.M. (A) Average assembly plot of 
mEmerald-Vcn at FAs for all cells. (B) Average disassembly plot of mEmerald-Vcn at FAs for 
79 
 
all cells. (C) Average assembly plot of mRFP-MVcn at FAs for all cells. (D) Average 
disassembly plot of mRFP-MVcn at FAs for all cells. (E) Representative assembly plot of 
mEmerald-Vcn at FAs for a single cell. (F) Representative disassembly plot of mEmerald-Vcn at 
FAs for a single cell. (G) Representative assembly plot of mRFP-MVcn at FAs for a single cell. 
(H) Representative disassembly plot of mRFP-MVcn at FAs for a single cell. Data pooled from 3 
independent experiments (n ≥ 13 cells (or at least 500 adhesions); *p<0.05; ***, p<0.001; not 






Figure 24. Focal adhesion assembly and disassembly rates display consistent results with 
the same tagged fluorophore. 
 (A) Western blot shows equivalent expression level of either mEmerald-Vcn or mEmerald-
MVcn in Vcn-null MEF background. (B) Representative time-lapse image sequences of Vcn-null 
MEFs stably expressing either mEmerald-Vcn or mEmerald-MVcn migrating on 10 µg/ml FN. 
Images are taken every 15 sec and show individual FA. Scale bar = 10 µm. Graph showing 
average rate constants of FA assembly (C) and disassembly (D) in each cell type. Data pooled 





MVcn-expressing cells lack a significant cell stiffening response to external force  
Vcn is a mechanotransducing protein known to play an important role in force transmission by 
linking transmembrane receptors to the actin cytoskeleton (141-144), and knocking out Vcn leads 
to decreased traction force at FA (32). Previous work demonstrated that Vcn bears force between 
the head and tail domains, and that the Vcn tail domain associates with actin filaments in cells, 
which has been shown to play an important role in cell traction force (32, 77, 105). In addition, 
cells expressing Vcn were previously shown to respond to external force by displaying a cell 
stiffening response in 3D force microscopy (3DFM) while Vcn-null cells failed to show this 
response (77, 101, 145).  Given these findings, we investigated whether MVcn was likewise 
involved in force transmission. To study how Vcn- and MVcn-expressing cells respond to external 
force, we used 3DFM (Fig. 25A) and assessed whether MVcn expression could restore the cell 
stiffening response in Vcn-null cells (77, 101, 145, 146). To test this, we applied uniform pulses 
of force to cells via attached FN-coated magnetic beads. Decreases in the relative bead 
displacements between the first and subsequent pulses were quantified to determine the cell 
stiffening response. Here, we ensured that the actual magnetic bead displacements were similar 
between individual cells (Fig. 26). Vcn-expressing cells revealed a stiffening response, which was 
absent in the Vcn-null cells, as expected based on previous findings (Fig. 25B) (101). Specifically, 
Vcn-null cells failed to show decreased bead displacement after the first pulse while Vcn-
expressing cells showed a 30% decrease in bead displacement between the first and second pulse 
of force (Fig. 25B). In contrast, MVcn-expressing cells did not exhibit a significant bead 





Figure 25. 3D-Force microscopy (3DFM) shows reduced ability of MVcn-expressing cells to 
rescue cell stiffening response compared to Vcn-expressing cells. 
(A) 3D-force microscopy (3DFM) setup used to measure cell stiffening response. Constant force 
was applied for 5 sec intervals followed by 10 sec relaxation; this pattern was repeated for a total 
of 5 pulses. (B) Cell stiffening response is measured by quantifying the decrease in bead 
displacement after each subsequent pulse of magnetic force in Vcn-null, Vcn-, and MVcn-
expressing cells. Cell stiffening response is lost in MVcn-expressing cells. Data pooled from 3 





Figure 26. 3DFM experimental set-up and controls. 
(A) Actual image of the experimental set-up. (B) Comparison of actual bead displacements 
between the first and second pulses for all cell types. Actual bead displacements between the first 
pulses of all cell types are similar. (C) Graph showing the relationship between the magnetic 
force experienced by the bead and the distance between the magnetic pole tip and the bead. Data 





Vcn and its splice isoform, MVcn, have been studied at both the tissue level and the 
molecular level (42, 83, 84, 90, 93-95, 97, 99, 103). However, a direct comparison of their behavior 
in cells is lacking. MVcn is co-expressed with Vcn at sub-stoichiometric levels in smooth and 
cardiac muscles, where the expression level correlates with the contractile needs of the cell (42, 
81, 84). The presence of MVcn in muscle cells is key, as mutations in the 68-residue insert lead to 
defects in the organization of intercalated discs and results in cardiomyopathy (90, 91). These 
observations have led to the idea that MVcn coordinates with Vcn to support force transmission in 
cells (84, 90, 91). Both Vcn and MVcn are localized to cell-cell and cell-matrix adhesion sites. 
How Vcn is recruited to cell-cell junctions is not completely understood, but the interaction 
between Vcn head domain and α-catenin is thought to play an important role. Vcn does not localize 
to cell-cell junctions in cells lacking α-catenin or in hearts lacking α-catenin (147, 148). Force is 
also thought to play an important role in the recruitment of Vcn to these cell-cell contacts as α-
catenin undergoes a force-dependent conformational change that exposes Vcn binding sites (149, 
150), and α-catenin is believed to play a role in Vcn activation at cell-cell junctions (151). Because 
the head domains of Vcn and MVcn are the same, it is likely that MVcn’s ability to interact with 
α-catenin is not altered. However, the difference in the cell’s ability to respond to force between 
cells may arise from potentially different ligand interactions of Vcn and MVcn, as the actin-
regulating proteins (such as VASP) that bind to the proline-rich linker region in Vcn may not bind 
to MVcn due to the extra 68-residue insert near that region.  
At the molecular level, MVcn has been proposed to fine tune force transmission by 
negatively regulating Vcn-mediated actin bundling (103). We and others have shown that in vitro, 
Vcn tail-mediated actin bundling is decreased as the MVcn tail concentration is increased (99, 
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103).  These findings suggest that MVcn may play a role in limiting, rather than strengthening, 
force transmission via Vcn tail-mediated actin bundling (99, 103). MVcn tail has similar actin 
filament binding properties as Vcn tail, but does not dimerize and so does not bundle actin 
filaments (90, 95, 97-100, 103).  These observations raise the following question. Is it possible 
that tail domain of MVcn competes with the Vcn tail domain in binding to actin filaments, 
providing a possible mechanism for modifying force transmission?  However, before attempting 
to understand the role of MVcn in the context of Vcn, it is necessary to clarify the role of MVcn 
in cells. To start, due to the lack of information regarding how Vcn and MVcn compare at the 
cellular level, we investigated whether stable expression of either Vcn or MVcn in a Vcn-null MEF 
background affects various cellular properties, including cell mechanotransduction. We find that 
both Vcn and MVcn are localized to the FA. As Vcn-talin interaction has been shown to be critical 
for the localization of Vcn to FA, this result is not surprising given that both proteins share the 
same head domain, which interacts with talin (47, 79, 82, 105). Our findings indicate that some 
functions are shared between Vcn and MVcn at the cellular level, such as the ability of MVcn to 
partially rescue the number of FA per cell (Fig. 17D) and fully rescue the cell spreading phenotype 
of Vcn-null cells (Fig. 19). However, several distinct phenotypes including FA size, cell migration, 
FA dynamics, and cell reinforcement are observed (Fig. 17D, 4, 5, and 6). These results suggest 
that similar phenotypes may be modulated by the shared head domain of the two proteins, while 
the distinct phenotypes may reflect their different tail domains. 
 We and others have previously shown that while Vcn tail can organize actin filaments into 
parallel bundles, MVcn tail organizes actin filaments into a mesh-like network instead of bundles 
(90, 95, 98, 99). The presence of the insert, including H1’, inhibits the ability of MVcn tail to 
bundle F-actin, as deletion of H1’ promotes actin filament bundling (95). This difference in actin 
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filament cross-linking between the two proteins likely plays a role in how cells regulate FAs and 
force transmission. Of note, we have previously shown that expressing an actin bundling-deficient 
Vcn mutant (Vcn∆C5) in Vcn-null MEFs leads to defects in FA properties and decreased cell 
reinforcement in response to mechanical force (101). As MVcn-expressing cells show similar 
defects in FA properties and force response, the inability of MVcn to bundle actin filaments might 
explain some of the differences observed between MVcn- and Vcn-expressing cells.  
 
MVcn expression alters FA properties 
   
 We found that FAs in MVcn-expressing cells have a larger area but are fewer in number 
per cell compared to Vcn-expressing cells (Fig. 17). Similarly, we previously showed that Vcn∆C5 
expression in Vcn-null MEFs also results in larger mean FA area as well as fewer FAs per cell 
(101). While a direct comparison cannot be made due to differences in both expression levels and 
cell type used for these studies, these FA trends strongly suggest the importance of actin bundling 
in FA regulation. Furthermore, MVcn-expressing cells are similar to Vcn-null cells in that they 
have larger FA size and fewer FA number per cell compared to Vcn-expressing cells. In fact, Vcn-
null cells have the fewest FA number per cell out of all three cell types.  
 
MVcn expression affects mechanical response to force 
 
 In contrast to Vcn, expression of MVcn does not rescue the cell stiffening response in Vcn-
null MEFs (Fig. 25). 3DFM revealed that while Vcn-expressing cells showed almost immediate 
and significant decrease in bead displacement after the first pulse of force, MVcn-expressing cells 
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did not show a significant decrease in bead displacement in response to successive pulses of 
tension (Fig. 25). Similar to MVcn, when Vcn∆C5, an actin bundling deficient mutant, was 
expressed in Vcn-null MEFs, cells were similarly defective in their stiffening response, 
additionally supporting that Vcn tail-mediated actin bundling is important for cell reinforcement 
(101). It is possible that Vcn tail-mediated actin bundling is necessary for aligning actin in the 
regions of high tension. Recent studies using talin FRET sensors and cellular cryotomography 
demonstrated that regions of high talin tension had highly aligned linear actin filaments, while 
regions of low tension showed less well-aligned actin filaments in cells (152). However, the ability 
of MVcn-expressing cells to maintain stress fiber structure suggests that the presence of other 
actin-crosslinking proteins, such as α-actinin and myosin, may contribute to the formation and 
maintenance of stress fibers within these cells (153, 154).  
 
MVcn expression alters cell migration and FA dynamics 
 
Does the inability of MVcn to bundle actin filaments account for most of the differences 
observed between Vcn- and MVcn-expressing cells? Our data showing differences in migration 
phenotypes suggest that other factors may be involved. While Vcn-null and MVcn-expressing cells 
migrated faster than Vcn-expressing cells, consistent with a negative regulatory function of MVcn 
tail, the migratory paths associated with MVcn-expressing cells displayed increased persistence 
relative to both Vcn-null and Vcn-expressing cells (Fig. 19). MVcn in these cells also had slower 
assembly and disassembly rates in FAs compared to Vcn in Vcn-expressing cells (Fig. 22). It has 
previously been shown that Vcn can facilitate FA formation and turnover (32), consistent with our 
findings that Vcn-expressing cells had smaller but more FAs per cell and faster FA assembly and 
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disassembly rates, respectively. However, this is a curious result as increased FA turnover has been 
typically associated with faster cell migration, but the MVcn-expressing cells migrate faster than 
the Vcn-expressing cells.  This could be partly due to differences in the ability of each isoform 
to engage particular binding partners. Moreover, the lack of Vcn-mediated actin bundling in 
MVcn-expressing cells may be compensated for by other actin-bundling proteins.  
In conclusion, we find that MVcn can rescue some of Vcn’s functions in Vcn-null cells. 
Targeting FAs, it rescues cell area.  Moreover, while MVcn partially rescues FA number, it is 
unable to fully rescue FA area. It also fails to restore the cell stiffening response to mechanical 
force in Vcn-null cells. Some of these differences may be due to the ability of MVcn and Vcn to 
engage distinct binding partners at the proline-rich linker, such as Arp2/3 complex, vinexin, or 
VASP, as the presence of the MVcn insert at the tail domain may disrupt these interactions that 
occur with Vcn. Additionally, it is possible that the additional MVcn insert introduces new 
interactions with other unknown ligands. However, the properties of MVcn-expressing cells are 
strikingly similar to those of cells expressing a Vcn mutant construct that can bind but not bundle 
actin filaments (101). Consequently, we currently favor a model that attributes the different 
phenotype of the MVcn cells to be largely due to the inability of MVcn to bundle actin filaments. 








CHAPTER 4 – Conclusions and Future Directions 
Overview 
 The overall goal of this dissertation was to determine the role of metavinculin in actin 
reorganization and force transmission. By using both in vitro biochemical and cell biology 
techniques, we have shed light on the mechanism of MVt-actin interaction and determined how 
the expression of metavinculin in MEFs leads to different phenotypes compared to vinculin 
expression. Our findings, reported in Chapter 2 and 3 of this dissertation, revealed that 
metavinculin’s functions are distinct from those of vinculin at both the structural and cellular 
level. These results raise new questions that we are interested in pursuing. In this chapter, I will 
first summarize our findings and potential impact, and then discuss the ongoing studies and 
future directions. I hope that the work presented here will contribute to the field of 
mechanotransduction and set the stage for future studies elucidating the coordinated role of 
metavinculin and vinculin under physiological settings. 
 
Review of Current Findings 
 We examine the role of metavinculin at both the molecular and cellular level in 
comparison to vinculin. First, we solved cryo-EM reconstructions of both MVt-actin and Vt-
actin complexes, in collaboration with the Alushin lab at Rockefeller University. These 
reconstructions revealed, for the first time, how both Vt and MVt interact with F-actin. We 
showed that while both Vt and MVt bind to actin filament at the similar interface, H1 in Vt and 
H1’in MVt, disengage from the rest of the helix bundle upon binding to F-actin.  In the case of 
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Vt, we hypothesize that helix partitioning exposes a new interface that facilitates Vt-dimerization 
and actin bundling. These findings not only provided valuable insight into the Vt-actin and MVt-
actin binding interfaces but also important mechanistic insight regarding large scale 
conformational changes in Vt and MVt that occur upon actin binding. Our cryo-EM 
reconstructions, in combination with biochemical data, indicate that F-actin engagement with the 
Vt and Mt helical bundle causes a torqueing conformational change, prompting H1 and H1’, 
respectively, to disengage from the rest of the helix bundle. We postulate that this 
conformational change exposes a cryptic dimerization site on Vt that allows for actin-bound Vt 
to dimerize, ultimately bundling actin filaments into parallel bundles observed in vitro (99). 
However, in the case of MVt, we believe that the presence of MVt insert interferes with the 
formation of this cryptic dimerization in MVt-actin complex by forming a protruding structure 
with H1, thereby disrupting the ability of MVt to bundle actin filaments in vitro (95). Overall, we 
hypothesize that Vt and MVt partially unfold upon actin-binding, but in the case of Vt, this 
rearrangement reveals a cryptic dimerization site that allows for Vt-mediated actin bundling, 
whereas in MVt, the partitioned H1 helix forms a globule domain that prevents MVt 
dimerization. Based on this conceptual model, we then studied how Vt-mediated actin bundles 
would be affected in the presence of WT MVt or CM-associated MVt mutants (A934V, ∆L954, 
and R975W). Through actin co-sedimentation assay and EM studies, we showed that the level of 
Vt-mediated actin bundles decreases in the presence of MVt WT. In contrast, MVt CM mutants 
did not inhibit Vt-mediated actin bundling, but rather, promoted higher actin assemblies. Hence, 
while MVt WT suppresses formation of Vt-mediated actin bundles, MVt CM mutants retain 
and/or enhance higher order actin structures (90, 99, 103, 155). This led us to hypothesize that 
MVt WT may negatively regulate the actin bundling properties of Vt, and that loss of negative 
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regulation by MVt CM mutants may contribute to HCM and DCM. At the molecular level, DMD 
simulations suggest that the extra residues on MVt may form a protruding structure that sterically 
prevents dimerization with another actin-bound Vt or MVt (155). Figure 16 highlight our model 
for how MVt WT or MVt CM mutants regulate actin bundling in the presence of Vt.  
Next, we studied how vinculin and metavinculin functions differ at the cellular level. To 
establish a system of cellular comparison, we generated vinculin null MEFs that stably express 
either fluorescently-tagged vinculin or metavinculin. We controlled for the expression levels of 
both proteins in these cell lines by sorting the cells via flow cytometry. After ensuring that the 
expression levels between vinculin and metavinculin were comparable, we examined the focal 
adhesion properties, cell migration, and mechanotransduction of these cells. Though we initially 
sought to use smooth muscle or cardiac cells as a system of comparison, the difficulty in 
maintaining and controlling for metavinculin expression in cell culture prevented us from using 
those cells. In smooth and cardiac muscle cells, metavinculin loses expression in cell culture 
unless the contractile environment is mimicked properly (84). On the other hand, the vinculin-
null MEF background allowed us to manipulate the expression levels of either vinculin or 
metavinculin. Results from our analyses indicate that metavinculin expression can fully rescue 
cell area and partially rescue FA number per cell. However, compared to vinculin-expressing 
cells, metavinculin expression led to larger individual FA area, faster cell migration, and 
decreased cell stiffening in response to external force. Our results suggest both overlapping and 




Significance of this dissertation 
This dissertation provides further insight into both molecular and cellular functions of 
metavinculin. First, the cryo-EM reconstructions of MVt-actin and Vt-actin complex provided an 
important insight into the critical interactions of both vinculin isoforms with filamentous actin. 
We found that helix Vt H1 or MVt H1’ undocks upon actin binding and determined important 
mechanistic insight into conformational changes that control higher order actin assembly. We 
believe that this unfurling generates a docking site for vinculin tail dimerization required for 
vinculin’s actin bundling activity. In the case of MVt, helix 1’ unfurling due to actin binding 
facilitates formation of a protruding structure that sterically prevents the dimerization with 
another Vt, ultimately preventing MVt-mediated actin bundling. This structural model can also 
explain MVt’s lack of actin bundling in the absence of Vt, and the suppression of Vt-mediated 
actin bundling in the presence of Vt. Extending this model into MVt CM mutants, this steric 
occlusion model can also explain the actin bundling we see in the presence and absence of Vt. 
We hypothesize that released H1’ and the upstream sequence (including MVt H1) play an 
important role for the inhibitory functions of MVt in Vt-mediated actin bundling by forming a 
protruding structure. However, CM mutants are all located within the insert either directly in H1’ 
or very close to H1’ (N-terminal strap), and are distal from the direct actin-binding region in the 
rest of the MVt helix bundle. Therefore, we suggest that MVt CM mutants destabilize this insert-
dependent globular structure and compromise MVt’s regulatory function to inhibit Vt-mediated 
actin bundling without disrupting actin binding.  
With this distinct structural difference between Vt and MVt in vitro, we wanted to 
determine whether this finding was significant in a cellular context. Hence, the second part of 
93 
 
this dissertation focused on developing a cellular system that can establish a systematic 
comparison between vinculin and metavinculin. 
Comparison of vinculin and metavinculin in vinculin-null MEFs is an excellent starting 
point for determining the difference between cellular functions of the two isoforms. This is 
because vinculin and vinculin-null MEFs have been extensively characterized in MEFs, allowing 
us to make direct comparisons of complex properties at the level of FAs and whole cells. To 
reduce complexity associated with interpretation of adhesion and cellular phenotypes and as a 
first step toward evaluating function in muscle cells, we compared the behaviors of vinculin and 
metavinculin in cells that lack each component. In different cardiac and smooth muscles, the 
ratio of vinculin and metavinculin differs physiologically based on the contractility of the tissue, 
in which metavinculin is sub-stoichiometrically expressed at ~9-42% of vinculin expression and 
its expression level is higher in more contractile tissues. From this simpler system, we showed 
that metavinculin-expressing cells have different static and dynamic FA properties as well as 
different cell migration patterns. Moreover, they lack cell stiffening response to external force 
relative to vinculin-expressing cells. This is the first effort to elucidate the role of metavinculin in 
regulating cell function, and results suggest important potential implications in understanding 
vinculin-mediated mechanotransudction. Therefore, this study may stimulate further research 
and questions based on the novel cellular results of metavinculin functions. 
Another interesting observation from these cellular studies with metavinculin-expressing 
cells is that metavinculin-expressing cells share much of the similar phenotypes as vinculin-null 
cells expressing vinculin ∆C5 mutant, which retains actin-binding but is deficient in actin-
bundling. Metavinculin-expressing cells, much like cells expressing vinculin ∆C5 mutant, have 
larger and fewer average number of FAs per cell. Additionally, metavinculin-expressing cells 
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also do not stiffen in response to externally applied force, similar to cells expressing vinculin 
∆C5 mutant. These observations point to similarities between the two cell types, suggesting that 
some of the cellular characterizations we see in metavinculin-expressing cells may be due to the 
lack of actin-bundling by metavinculin.  
Ultimately, we would like to explore the possibility of metavinculin’s function in 
negatively regulating vinculin-mediated actin bundling in cells, based on our in vitro actin co-
sedimentation assay results where the presence of MVt suppressed the Vt-mediated actin bundles 
(99). Our long-term goal is to determine whether the two proteins interact competitively in cells. 
With only a difference of a single exon between the two proteins, we find that it is significant 
that this 68-residue difference leads to changes in multiple phenotypic properties. Our study 
serves as a key starting point for ultimately examining differing vinculin and metavinculin ratios 





 Though these findings provide an important starting point for distinguishing the 
functional differences between vinculin and metavinculin, much remains to be studied. Hene, in 
this section, I discuss several exciting components of this project that we hope to pursue in the 
future. 
First, we would like to explore whether vinculin and metavinculin possess distinct 
binding partners. Based on our structural, computational, and biochemical studies on 
metavinculin, we hypothesize that the insert region present in metavinculin may potentially 
disrupt the interactions that vinculin typically makes with other molecules within the proline-rich 
linker, as the proline-rich linker is a disorganized region that immediately precedes the 
metavinculin insert. Actin-induced structural element lies proximal to the proline rich region, 
which contains multiple interaction sites, including vinexin, VASP, and Arp2/3. If metavinculin 
insert does form a protruding structure as the DMD modeling suggests (155), it is possible that 
the proline-rich region of metavinculin and vinculin differ in their ability to interact with ligands. 
On the other hand, the metavinculin protruding structure may also facilitate new interactions. We 
would like to clarify this question by first examining the known ligands that bind to vinculin 
proline-rich linker with metavinculin. 
Second, with recent insights into metavinculin functions, it will be important to determine 
how the presence of both metavinculin and vinculin modulates cellular functions. Because 
metavinculin is always co-expressed with vinculin at sub-stoichiometric ratio dependent on the 
contractility level of the tissue (83, 84), it is more physiologically relevant to determine functions 
of metavinculin in the context of vinculin in cells. Additionally, based on MVt’s suppression of 
Vt-mediated actin bundling in in vitro studies, we suspect that metavinculin plays an important 
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role in negatively regulating vinculin-driven actin bundling in cells. Therefore, we plan to 
examine the properties of cells that express both metavinculin and vinculin at different ratios. 
Stable cell lines have been established for vinculin-null MEFs that co-express fluorescently 
tagged vinculin and metavinculin, and these cells have been sorted based on the expression 
levels of each protein. In these cells, vinculin expression levels remain constant and are 
comparable to the vinculin expression in WT MEFs. However, it will be important to vary the 
co-expressing metavinculin expression in these cells to examine effects of different vinculin to 
metavinculin ratios on cells. To mimic the physiological expression of vinculin and 
metavinculin, expression of vinculin will be kept constant close to the WT vinculin expression 
level and the expression of metavinculin will be varied at sub-stoichiometric ratios relative to 
vinculin (~9-42%). We are curious to know whether metavinculin expression translates into 
cellular phenotypes that are indicative of metavinculin’s function in inhibiting vinculin-mediated 
actin bundling. Specifically, we will examine FA properties, cell migration, cell spreading, and 
mechanotransduction of the co-expressing cells and compare them to the results of the cells that 
stably express either vinculin or metavinculin. It will be interesting observe whether the co-
expressing cells behave more similarly to metavinculin-expressing cells as the ratio of 
metavinculin increases in these cells. If metavinculin’s primary function is to negatively regulate 
vinculin-induced actin bundling, we expect that as the metavinculin expression increases, these 
cells will exhibit larger but fewer FAs per cell, faster and more persistent cell migration, and 
decrease in cell stiffening in response to external force. 
Next, we would like to characterize the cellular functions of vinculin-null MEFs that 
express metavinculin CM-associated mutants either in the presence or absence of vinculin. 
Currently we have generated vinculin-null MEFs that stably express only metavinculin A934V, 
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∆L954, or R975W to determine the effect of metavinculin mutant in these cells. Because we 
observed that MVt CM-associated mutants weakly induce the formation of disordered actin 
filament assemblies in vitro, we would like to examine whether this disordered actin assembly 
formation has any effect on cellular functions. We have additionally generated stable cells that 
co-express fluorescently tagged WT vinculin and one of the three metavinculin mutants (A934V, 
∆L954, or R975W) to determine the effect that metavinculin CM-associated mutants have on 
cells in the presence of vinculin at sub-stoichiometric levels. Through in vitro studies, we have 
found that these mutants fail to inhibit Vt-mediated actin bundling and instead promote 
formation of large assemblies. Based on these in vitro results that affect actin bundling, we 
suspect that expressing metavinculin CM-associated mutants in cells that co-express vinculin 
may cause defects in FA properties, cell migration, and mechanotransduction properties.  
Ultimately, we would like to extend to more physiologically relevent cellular studies. As 
metavinculin is specifically expressed in cardiac and smooth muscle cells, MEFs do not provide 
the most applicable information in terms of how metavinculin functions in the context of muscle 
cells. However, we believe that comparison of vinculin and metavinculin in MEFs is an excellent 
starting point at this point in the project. Vinculin functions in MEFs and vinculin-null MEFs 
have been well-characterized in the field, and this allows us to compare behaviors of vinculin 
and metavinculin in cells that lack each component in a simpler system. Furthermore, 
metavinculin and vinculin are scaffold proteins that interact with multiple ligands. While we are 
currently focused on actin, other ligands may play different roles as well. Other differences such 
as how their expression and splicing is controlled based on cell type, may be important to 
investigate. Moreover, cell adhesion, migration and mechanotransduction properties are 
complicated processes, and differnces here will require further study. In different cardiac and 
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smooth muscles, the ratio of vinculin to metavinculin differs physiologically based on the 
contractility of the tissue (83, 84). For example, high levels of metavinculin expression were 
found in smooth muscles of human uterus and aorta, while no metavinculin expression was 
observed in nonmuscle cells, such as liver, foreskin fibroblasts, and peritoneal macrophages (84). 
Additionally, culturing aortic medial cells leads to the loss of metavinculin expression, as this 
causes the cells to lose contractility (84). Therefore, we hope to address this complex but 
necessary problem in future studies by ultimately applying this system to smooth or cardiac 




Speculations on metavinculin 
 In this last section, I would like to discuss aspects of metavinculin that I find curious but 
have not had a chance to pursue. The existence of metavinculin as a splice isoform of vinculin is 
fascinating, since metavinculin is an isoform that originates from the same gene as vinculin with 
the only difference from vinculin being the expression of the exon 19. The expression of 
metavinculin, in which the presence of exon 19 is the only difference relative to vinculin, in 
vinculin-null MEFs was sufficient to change cellular phenotypes compared to vinculin-
expressing cells. That metavinculin is expressed from the same gene as vinculin and has only a 
single exon difference makes me speculate that metavinculin must possess a distinct, important 
function that vinculin lacks. 
I will first briefly discuss the evolutionary perspective of cell adhesion in the context of 
vinculin and then go on to provide my perspective on how metavinculin may have evolved. 
Cell-matrix adhesion and cell-cell interaction are important for mutlticellularity from an 
evolutionary perspective, as adhesion molecules anchor cells and tissues to secreted ECM and 
cell-cell adhesion molecules connect adjacent cells within tissues. Both focal adhesions (FAs) 
and adherns junctions (AJ) differ in protein composition, but both junctions contain vinculin. 
The similar architecture of both FAs and AJs throughout animals suggest that these structures 
evolved early. Some of the earliest cell adhesion experiment were done on sponges, and in 1907 
Wilson famously demonstrated that cells from dissociated sponge tissues can re-aggregate and 
develop into a functional organism (156). Instead of FA and AJ adhesion molecules, sponges 
secrete proteoglycan complex called the aggregation factor (AF) that functions in both cell 
adhesion and self/non-self recognition (157-161). Core proteins of AF consist of calx-beta 
domains and sponge-specific “wreath” domain (162). Predominant adhesion mechanism in 
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sponges are considered to be the sulfated polysaccharide components of the AF that undergo 
calcium-dependent, hemophilic interactions (163). Although the differences between the AF 
model of sponges and FA or AJ adhesions in other animals contribute to the view that sponge 
tissues lack the organizational level found in epithelial cells, other comparative genomics studies 
demonstrate that sponges share homologs of core FA and AJ proteins, including those of 
vinculin (164). Miller et al. have recently found an orthalog to a vertebrate vinculin in the sponge 
Oscarella pearsei (Op) and examined the structure, biochemical properties, and tissue 
localization of this Op vinculin (164). Results from this study indicated that Op vinculin localize 
to both cell-cell and cell-ECM contacts and had similar biochemical and structural properties as 
vertebrate vinculin (164). They proposed that Op vinculin played a role in cell adhesion and 
tissue organization in the last common ancestor of sponges and other animals (164). These 
findings suggest that sponge tissues share similarities with epithelial tissue organization and that 
AJ- and FA-like structures extend to the earliest periods of animal evolution. 
When I consider the evolutionary perspective of cell adhesion, I suspect that 
metavinculin must have diverged from vinculin after vinculin evolved as a component of the cell 
adhesion since vinculin sequence is conserved across most species. While vinculin itself is 
highly conserved among most species, greater sequence variation is observed in the metavinculin 
insert region among vertebrate species compared to the rest of the sequence (165, 166). Despite 
this sequence variation in the metavinculin insert region, it should be noted that the C-terminal 
region of the insert that contains MVt H1’ helix is identical in higher vertebrate species. This 
sequence alignment in MVt H1’ helix among species suggests that metavinculin helix H1’ 
possesses a unique physiological function of the tail domain. Unfortunately, studies on the 
evolution of metavinculin is currently lacking, which limits my speculations. However, 
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considering that vinculin has orthologs in sponges, I surmise that metavinculin may be a separate 
isoform that was evolved in vertebrates as metavinculin has been found in most vertebrates, 
including but not limited to mice, cattle, rabbits, whales, bats, and birds. I have not yet been able 
to find any references on metavinculin sequence conservation in sponges, which suggests to me 
that metavinculin may have evolved in Metazoans (major division of the Animal Kingdom that 
comprises all animals other than Protozans and sponges). Examination of how metavinculin 
splicing occurs may provide more insight into the function of metavinculin and the evolutionary 
perspective of metavinculin in the future. 
Another interesting aspect of vinculin and metavinculin is their roles in platelets. Both 
vinculin and metavinculin are found in megakaryocytes and platelets (81, 167, 168). Unlike most 
other cell types, platelets lack nuclei and are non-migratory. Instead, platelets roll, adhere, 
spread, and aggregate following a vascular injury as their main physiological role is to promote 
hemostasis by forming thrombi at sites of vessel injury.Vinculin is thought to play an important 
role in the structural reorganization of human platelet cytoskeleton upon platelet activation as it 
is incorporated into platelet cytoskeleton from cytosol upon thrombin-stimulated activation of 
the platelets (169). However, based on the more recent study using vinculin-deficient platelets, it 
seems that vinculin is not required for the traditional functions of αIIbβ3 or the platelet actin 
cytoskeleton, and vinculin may be more important for maintaining membrane cytoskeleton 
integrity in platelets under mechanical force (170). Because platelets do not engage in the same 
type of cell migration as the nucleated cells that migrate extensively during development (where 
migration is vinculin-dependent), perhaps the function of vinculin in actin cytoskeleton is 
different in platelets. Similarly, perhaps the function of metavinculin in platelets is different 
compared to those in smooth and cardiac cells as well. Rather than playing a role in force 
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response and actin contractility, perhaps the presence of metavinculin in platelets has a function 
in the maintenance and regulation of actin network organization at different stages of platelet 
activation.  
Finally, though characterizations on MVcn-expressing cells were focused on cell-matrix 
adhesions, MVcn’s roles may be more physiologically relevant for cell-cell adhesions. Not only 
that, but studies show that the balance of cell-cell and cell-matrix adhesions is critical for proper 
development (171). Studies have shown that there is considerable cross talk between cell-cell 
and cell-matrix adhesion sites with changes in adhesion and force transmission (172, 173). As 
vinculin and metavinculin (in muscle cells) localizes to both cell-cell and cell-matrix adhesion 
sites (sarcomeres and intercalated discs in muscle cells), it is likely that these proteins participate 
in this cross talk. One interesting point to note about the cross talk between cell-cell and cell-
matrix adhesions is that adhesion/force transmission changes at one site does not always equate 
to changes at the other. For example, expanding the density of vascular endothelial cells plated 
on substratum increases cell-cell contacts but decreases cell-matrix adhesions (174). In cardiac or 
smooth muscle tissues, cell-cell contacts play a critical role in maintaining proper force 
transmission as uniform contractile response is necessary for their functions. As metavinculin 
expression led to fewer FAs per cell (fewer cell-matrix adhesions) compared to vinculin-
expressing cells, perhaps one function of metavinculin in cardiac and smooth muscle cells is to 
limit FA formation to allow for stronger cell-cell adhesions. As decrease in metavinculin 
expression has been associated with disorganized intercalated discs and dilated cardiomyopathy 
(89), metavinculin’s role at cell-cell junctions is critical. It would be interesting to explore more 
about metavinculin’s function at not only cell-cell junctions but also in the cross talk between 
cell-cell and cell-matrix adhesions.  
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 This dissertation serves as a first step in understanding how these proteins function 
individually in cells. With a difference of a single exon between the two proteins, we find that it 
is significant that this 68-residue difference leads to changes in multiple cellular phenotypes. I 
hope that this dissertation is able to contribute to the metavinculin field and expand on the 
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